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    “Muad'Dib learned rapidly because his first training was in how to 
learn. And the first lesson of all was the basic trust that he could learn. 
It's shocking to find how many people do not believe they can learn, 
and how many more believe learning to be difficult. Muad'Dib knew 
that every experience carries its lesson.” 
Dune, Frank Herbert, 1965 
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Abbrevations 
Abeta – Amyloid beta peptide. 
AbetaNG – Non glycated Abeta. 
AbetaG – Glycated Abeta. 
AD – Alzheimer disease. 
AFM – Atomic force microscopy. 
AGEs – Advanced glycation end products. 
ANTS – 8-aminonaphthalene-1,3,6-trisulfonic 
acid. 
APP – Amyloid precursor protein. 
CD – Circular dichroism spectroscopy. 
Chol – Cholesterol. 
COSY – Correlation spectroscopy. 
CSI – Chemical shift index. 
DMSO – Dimethyl sulphoxide. 
DOPC – 1,2-dioleoyl-sn-glycero-3-
phosphocholine. 
DPX – p-xylene-bis-pyridinium bromide. 
E.Coli – Escherichia Coli. 
EM – Electron microscopy. 
ESR – Electron spin resonance. 
FTIR – Fourier transform infrared spectroscopy. 
GM1 – Monosialic ganglioside. 
ThT – ThioflavinT. 
HFIP – Hexafluoroisopropanol. 
HN – Amide proton. 
Hp – Hemopressin. 
HSQC – Heteronuclear single quantum coherence 
spectroscopy. 
IBs – Inclusion bodies. 
IPTG – Isopropyl β-D-1-thiogalactopyranoside. 
LB – Luria-Bertani broth. 
Ld – Fluid-disordered phase. 
Lo – Fluid-ordered phase. 
LUV – Large unilamellar lipid vesicle. 
MD – Molecular dynamics. 
MGO – Methylglyoxal. 
MW – Molecular weight. 
n-PCSL – Spin-labeled phosphocholines. 
NaP – Sodium phosphate buffer solution. 
NMR – Nuclear magnetic resonance spectroscopy. 
NOESY – Nuclear Overhauser effect spectroscopy. 
RVD-Hp – RVD-Hemopressin. 
PAGE – Polyacrylamide gel electrophoresis. 
POPC – 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine. 
POPS – 1,2-diacyl-sn-glycero-3-phospho-L-serine. 
PUFA – Polyunsaturated fatty acids. 
TFE – Trifluoroethanol. 
ROESY – Rotating-frame Overhauser 
spectroscopy. 
S – Lipid segmental order parameter. 
SDS – Sodium dodecyl sulphate. 
SM – Sphingomyelin. 
TFA – Trifluoroacetic acid. 
Tm – Melting temperature. 
TOCSY – Total correlation spectroscopy. 
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Chapter 1 – Introduction 
 
1.1 Protein aggregation 
The importance of protein aggregation has increasingly gained interest in the last 20 
years, due to the discovery that the formation of amorphous or fibril-like protein 
aggregates are involved in many different cellular processes.  
Data gathered on this topic in the recent years show that an increasing number of 
pathologies are associated with protein aggregation and that aggregation often occurs 
through misfolding rather than just unfolding. A very important class of protein 
aggregation related diseases are amyloidoses, of which the more studied are 
Alzheimer’s disease, Huntington’s disease, Bovine Spongiform Encephalopathy, 
familial amyloid polyneuropathy and Parkinson’s disease [1]. Extensive studies show 
that all amyloid diseases are characterized by assemblies containing extremely 
insoluble protein fibrillar aggregates that share similar morphological features but 
comprise many different proteins with no obvious sequence similarity, called amyloid 
fibrils (see Table 1-1) [2,3].  
The interest in protein aggregation is, however, not limited to its medical implications. 
Many more proteins than those known to be implicated in human diseases have been 
found to lead to amyloid fibrils, suggesting the hypothesis that most, if not all, amino 
acid sequences might be able to misfold in a similar ordered way. This evidence places 
protein misfolding into a much wider perspective [4]. 
It has also been recently shown that protein aggregation is not always dangerous: 
formation of essential cellular bodies such as melanosomes and dendritic cell 
aggresome-like structures depends on protein aggregation [5]. Moreover, some 
cellular protein interactions involve the formation of amyloid-like structures and 
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several protein and peptide hormones are stored in the cell in amyloid-like structures 
[6].  
One of the main features of all amyloid protein deposits, both functional and disease-
related, is their ability to display positive apple green birefringence under polarized 
light after binding amyloidophilic dyes such as Congo red [7,8] or ThioflavinT (ThT) 
[9]. Electron Microscopic (EM) examination of amyloid fibrils revealed that fibrils 
are 5-10 nm in width and of indefinite length [10,11]. X-ray diffraction analysis 
revealed a so-called cross- diffraction pattern [12], showing that the fibrils are 
ordered in a pleated sheet conformation, with the direction of the polypeptide 
backbone perpendicular to the fibrils’ axis. The structural similarity of amyloid fibrils 
suggests that the key elements of the aggregation process may be common to all 
proteins involved. However, the molecular basis underlying amyloid aggregation are 
still poorly understood [13], making more difficult  the identification of the 
therapeutic targets for treating amyloid diseases. Moreover, recent studies have shown 
that the amyloid toxicity could be related to the formation of soluble oligomeric 
species during the amyloid fibrils formation process, with the latter relatively inert 
compared to their oligomeric counterparts [14]. Whether oligomers are precursors to 
fibrils or form along a separate pathway is a subject of current research and academic 
debate [15]. Therefore, it is critical to understand the mechanisms of these processes 
at a molecular level, in order to find a rationale for the structure-related toxicity of 
amyloid fibrils. 
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Diseases  Involved proteins 
Alzheimer’s Disease  Amyloid β-protein 
Parkinson’s disease  α-Synuclein 
Creutzfeldt–Jakob disease  Prion protein 
Huntington’s disease  Huntingtin 
Familial Amyloid Polyneuropathy  Transthyretin 
Diabetes type 2  Amylin 
Amyotrophic lateral sclerosis (ALS)  Superoxide dismutase (SOD) 
 
Table 1-1 List of some amyloid-based diseases and their related proteins. 
1.2 Aim of the thesis 
This thesis aims to provide structural and biophysical insights on the molecular 
mechanism underlying amyloid aggregation. Three polypeptides were chosen as 
models for these studies, differing in size and molecular origin, but sharing the 
capability to form fibrillar aggregates, although starting from different conformations, 
therefore likely through different mechanisms. The main model is represented by 
amyloid beta peptides, in particular the 40 and the 42 residues peptides, henceforth 
called Abeta40 and Abeta42, which are related to Alzheimer disease. The ability to 
switch from -helical conformation in membrane and apolar environment [16,17] to 
-sheet fibril structure in aqueous solution characterizes these peptides  The second 
model is Hemopressin, a short peptide that shows very promising pharmacological 
application, hampered by its aggregation propensity; this peptide is unstructured in 
aqueous buffers, but it forms amyloid fibrils in specific conditions in vitro [18]. The 
third model is an engineered protein, called Y65R-MNEI, derived from monellin, very 
interesting for its potential biotechnological application as ipocaloric sweetener. Its 
structures is very close to that of the parent protein MNEI which, at native state, is a 
soluble globular protein rich in -sheet. MNEI is a well-known model for protein 
folding studies; moreover, after a partial unfolding event, it is also able to form 
amyloid fibrils [19].  
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These molecules were studied at different levels of deepness in literature, with many 
different biophysical techniques. The choice of these three models allowed me to 
study the amyloid aggregation process at different stages, using a combination of 
biophysical techniques widely used in protein aggregation studies. In particular, the 
effect of different physico-chemical parameters (temperature, ionic strength, pH and 
solvent polarity), of the interaction with membrane model systems and of the effect 
of non-enzymatic post-translational modification on the aggregation properties of 
these molecules was investigated. A literature review about the chosen models and a 
more detailed work outline are reported in this chapter. 
1.3 Amyloid  peptide 
Abeta peptide was first identified by Glemer and Wong in 1984 as the principal 
component of amyloid deposits present in the brain of patients affected by Alzheimer 
Disease [20]. Abeta has a peptide length of 39-43, with the majority of amyloid found 
in senile plaques having a peptide length of 40 and 42 residues [21,22]. The sequence 
of the two main Abeta peptides, Abeta40 and Abeta42, are shown in figure 1.1. 
Abeta40 is more soluble and aggregates slowly, while Abeta42 is a "sticky" β-amyloid 
peptide that rapidly forms insoluble clumps [23]. Abeta peptides are encoded by a 
gene on chromosome 21 as part of a larger transmembrane protein, named amyloid 
precursor protein (APP) [23]. The function of APP is unclear at this point, but research 
has suggested that APP may have a role as an autocrine factor to stimulate the 
proliferation of fibroblasts [24] and as a modulator of cell adhesion. In addition, APP 
is implicated in the regulation of intracellular calcium [25] metal ion homeostatsis 
[26], and cell growth [24]. Recently, Sanders and colleagues demonstrated that APP 
Figure 1.1 Abeta peptides aminoacidic sequences: Abeta40 sequence is coloured in red, the two 
more C-term residues present in Abeta42 are coloured in blue. 
NH2-DEAFRHDSGY10EVHHQKLVFF20AEDVGSNKGA30IIGLMVGGVV40IA-
COOH 
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may have a cholesterol-binding site with E693 and N698 accepting and donating 
hydrogen bonds to bind cholesterol, thus providing evidence that APP may have a 
role in cholesterol regulation and metabolism [27].  
Proteolytic cleavage of APP occurs in two distinct manners: via either the α-secretase 
pathway or the β-secretase pathway [28]. The former pathway involves neuronal 
secretion of sAPPα by a putative α-secretase enzyme that precludes the formation of 
full-length Aβ, as the cleavage occurs at level of the peptide bond corresponding to 
Abeta residues 16 and 17. Traditionally the α-secretase pathway has been called the 
non-amyloidogenic pathway since full-length Abeta cannot be formed anymore. Full-
length Abeta is generated when N-terminus of APP is sequentially cleaved by a β-
secretase and γ-secretase, releasing the amyloidogenic peptide in the extracellular 
space, traditionally called amyloidogenic pathway. APP metabolism by the β-
secretase pathway was initially proposed to be an abnormal proteolytic processing 
event specific to, and with a causative role, in AD. However, proteolysis of APP via 
the β-secretase pathway has been found to be a normal process, which occurs 
ubiquitously in both AD and non-demented individuals [29]. The location of the γ-
secretase cleavage site is variable, which causes the C-terminus of Aβ to vary between 
amino acids 39 and 43. A schematic view of this process is shown in figure 1.2. 
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This heterogeneous cleavage pattern can be explained by assuming that γ-secretase 
activity is due to multiple enzymes, or even that Abeta generation occurs in different 
cellular sites, where environmental conditions affect enzymes specificity [31]. 
1.3.1 Alzheimer’s Disease 
Alzheimer’s disease is a neurodegenerative disorder that results in progressive 
cognitive impairment, including dementia, personality changes, judgment, language 
skills and memory loss, eventually resulting in the death of the individuals.  
The pathology which would later be identified as AD was first described by Alois 
Alzheimer in 1907 [32]. A significant period of time elapsed between the time that 
Dr. Alzheimer identified the disease until any significant progress was made in the 
study of AD: it was not until the mid- to late 1980’s that the Abeta peptides were 
shown to be correlated with AD symptoms [21,33]. 
Pathologically, AD is identified post-mortem by the presence of extracellular amyloid 
plaques and intracellular neurofibrillary tangles. Research by Selkoe and others has 
shown that Abeta peptides are the primary constituent in these amyloid plaques, while 
hyper-phosphorylated tau protein is the primary constituent in neurofibrillary tangles 
[34]. Post mortem examinations of patients with AD symptoms have shown a 
Figure 1.2 Schematic view of APP proteolytic cleavage  [30]. 
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reduction in the physical size of the temporal and frontal lobes, hippocampus and 
amygdala, the regions involved in memory and learning process. This cerebral atrophy 
is the direct result of neuronal apoptosis and synaptic atrophy appearing concurrently 
with the presence of amyloid plaques and tau tangles [35]. In addition, inflammatory 
cytokines formed by degenerating neurons and activated microglia around the 
amyloid plaques may contribute to the symptoms associated with AD [35]. 
The exact mechanism by which Abeta produces neurodegenerative symptoms remains 
unclear, although several mechanisms have been suggested. The interaction between 
oligomeric Abeta peptides and lipid membranes is thought to have a central role in 
AD pathology [36-38]. Free radical production [39] and changes in lipid metabolism 
has been identified [40]. Other mechanisms that have been proposed are: induction of 
cell apoptosis [41] and the production of toxic levels of hydrogen peroxide [42].  
1.3.2 The Amyloid Cascade Hypothesis 
The notion that Abeta peptides are the causative agents in the etiology of AD has been 
a controversial one [43]. However, few researchers have managed to present 
alternative hypotheses that explain the majority of pathological and biophysical 
phenomena that are manifested in the progression of AD. The amyloid cascade 
hypothesis has been revised over time even though the basic precepts of the hypothesis 
remain intact (Figure 1.3). 
Few years after the identification of Abeta peptides as the major constituent in 
amyloid plaques, Hardy and Higgins proposed their hypothesis [44], suggesting that 
Abeta aggregation is the causative agent of AD and that all other phenomenon such 
as neurofibrillatory tangles, tau phosphorylation, vascular damage, neuronal death, 
dementia, and finally death, follow, in that order, from the over- production of Abeta 
[34,45]. A schematic view of the process is reported in figure 1.3. 
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One of the recurring criticisms of the amyloid cascade hypothesis is that it fails to 
explain the unequal distribution of amyloid deposition in the brain; many people have 
been observed to have neuronal amyloid plaques during post mortem autopsy without 
demonstrating any Alzheimer’s symptoms while they were alive [47]. Lastly, the 
amyloid cascade hypothesis is unable to explain why Alzheimer’s is an age related 
disease or why there are considerable vascular pathologies related to AD [48]. 
A number of revisions to the amyloid cascade hypothesis have been accepted by the 
research community without compromising the underlying premise that Abeta 
peptides are the causative agents of AD. Firstly, it is now widely accepted that small 
Figure 1.3 Amyloid Cascade Hypothesis scheme  [46]. 
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molecular weight aggregates are the most neurotoxic amyloid species rather than 
amyloid fibrils or amyloid plaques [49,50], leading some authors to refer to an 
“oligomer cascade hypothesis”.  
By the turn of the last century, many studies have shown that neuronal synapses were 
most affected by amyloid neurotoxicity by impairing potentiation as a result of the 
interaction between amyloid oligomers and the neuronal synapse [51,52]. In addition, 
recent studies shown that cytotoxicity is a generic effect of all amyloid oligomers [2] 
and is associated with the initial misfold of oligomers setting off the amyloid cascade 
[50,53]. 
A very nice analogy conceived by Selkoe figures the amyloid plaque like “jails” which 
neutralize toxic oligomers. Once the “jails” are full, there are too many oligomers for 
the “police” (neuroclearance mechanisms) to deal with and the oligomers can wreck 
their havoc on the brain. Attempting to prevent amyloid plaques would release the 
“bad guys” causing more damage (Selkoe, D. (n.d.). Amyloid hypothesis - beta 
oligomers and plaques. Retrieved 10 21, 2013, from DNA Learning Center: 
http://www.dnalc.org/view/2134-Amyloid-hypothesis-beta-oligomers-and-
plaques.html).  
Secondly, in late onset AD, the incorrect cleaving of APP into the more pathogenic 
Abeta42 form as opposed to the more stable Abeta40 has been linked to AD symptoms 
rather than the simply overproduction of them [47]. The amyloid cascade hypothesis 
assumes a linear progression of the disease; however, considerable evidence is 
mounting that different amyloid species with varying degrees of toxicities may lie 
along different reaction pathways. Factors such as metals catalyse the aggregation 
process along differing pathways.  
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 1.3.3 Abeta amyloid peptides structure 
The amyloid β peptide is considered as part of the Intrinsically Disordered Proteins, a 
class of protein characterised by lack of a unique 3D folding at physiological 
conditions; on the other hand, they show a very high structural polymorphism, which 
is largely dependent on the environment [54,55]. For these reasons, the field of 
structural studies of Abeta peptides is extremely complex and encompasses the 
structure of the soluble Abeta, its polymerization into intermediates and their 
assembly in amyloid fibrils that characterise the amyloid deposition in vivo. Structural 
studies of soluble Aβ have been performed using NMR, CD and FTIR methods to 
look at the structure of different regions of Abeta in various solvents. Atomic force 
microscopy (AFM) has proved a valuable tool to investigate the nature of the 
intermediates in the amyloid pathway. Transmission EM and fiber diffraction have 
been used to examine the structure of the amyloid fibrils, as well as methods of solid-
state NMR and FTIR.  
To structurally characterise the non-aggregated state of the Abeta peptides, tri-
dimensional structures have been obtained using smaller fragments in aqueous 
solution or full-length peptides in non-physiological conditions (pH, presence of 
strong organic solvents or detergents) to avoid protein aggregation. The N-terminal 
28-amino-acid fragment of Abeta was studied in detail by 1H-NMR in water–
trifluoroethanol (TFE) solutions and was found to have a predominantly α-helical 
structure [56]. NMR structures of Abeta40 and Abeta42 have been determined 
respectively in the presence of sodium dodecyl sulphate (SDS) micelles [17] and in 
hexafluoroisopropanol (HFIP)/water mixture [16] (figure 1.4). All these NMR studies 
revealed the presence of a large helical region, however the current model 
representing the structure of Abeta42 in an apolar environment hints to the presence 
of two helical regions encompassing residues 8–25 and 28–38, connected through a 
flexible kink or a regular type I β-turn. Thus, Abeta generally forms stable α-helical 
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conformation in organic solvents or in micelles, although the specific conformation 
can be affected by pH, concentration and incubation time.  
 
This structure is modified when the water amount is increased [57], and the presence 
of a β-sheet appears in the C-terminal region. Peptide aggregation and precipitation 
was observed to occur following β-sheet formation in a time dependent manner, 
indicating that formation of β-sheet structure is directly related to peptide aggregation 
[57-59]. β-Sheet formation by Abeta was observed to be strongly dependent on 
environmental conditions, and such factors inducing these structural changes were 
identified over the last few years [60]. For example, it was found that β-sheet 
formation and peptide aggregation of Abeta40 have pH dependence and were most 
rapid at pH 5.5. The observation that β-sheet formation by Abeta was promoted at low 
pH is, particularly, of interest as the pH in AD brain has been found to be slightly 
lower than in normal brain, and this acidosis may result in enhanced peptide 
deposition. The longer Abeta42 isoform instead aggregates more rapidly at pH 7.4, 
demonstration that the presence of two extra residues at the C-terminal changes 
dramatically its aggregation properties with respect to the other isoform. 
Figure 1.4 Solution structural models of Abeta40 in SDS micelles (left side, red ribbon, pdb code 
1BA4) and of Abeta42 in HFIP/water mixture (right side, black ribbon, pdb code 1IYT). 
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It may not necessarily be true that there is a distinct and reliable correlation between 
in vitro solution structure and Abeta deposition; however, particular conformational 
features in soluble, in vitro samples may contribute to a better understanding of Abeta 
deposition in AD. Studies on Abeta peptides in solution have revealed a common 
theme in which the soluble full length or fragments of the peptide convert from a α-
helical structure or random coil structure to a β-structure upon aggregation. 
The amyloid fibril appears to be a ubiquitous structure intrinsic to the protein 
backbone structure accessible to virtually any polypeptide sequence [4]. Despite a 
similar end structure, there seems to be no similarity among primary protein structure 
linking these proteins. Today, various methods including x-ray diffraction, NMR, 
AFM, and EM have shown that fibrils formed by different properties share similar 
properties. Mature amyloid fibrils are observed to be approximately 100Å in diameter 
and composed of 20–35Å wide protofilaments. 
Recent advances have allowed researchers to solve the structure of amyloid fibrils, 
even if fibrils structure is characterized by a very high polymorphism, both chemical 
[61,62] and biological [63]. A multistep seeding approach can be used to select a 
single, more stable fibril morphology [64]. Abeta peptides have a β-sheet secondary 
structure that stack in a parallel or anti-parallel fashion to form β-sheets running 
perpendicular to the fibril axis [12,65]. This is referred to as a cross- pattern [66]. 
One of the first amyloid fibrils structural model of Abeta42 was proposed by Riek 
group [61]. Figure 1.5 shows a 3D cartoon representation of a antiparallel structure of 
a single amyloid protofilament accordingly to Riek findings. A mature amyloid fibril 
is formed when these single protofilaments wrap around one another to form a 
multifilament fibril as shown in figure 1.6. 
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This model has been characterized as each monomer having an unstructured N-
terminal (1-16) region with two hydrophobic regions (16-23 and 28-35) connected by 
a loop region 24-27. An interior salt bridge forms between Asp23 and Lys28, 
detectable by both NMR and MD simulations. This salt bridge is imperative for the 
self-dimerization of Abeta and an important element of fibril structure [67]. 
Intermolecular interactions amongst the side chains are formed between the odd-
numbered residues of the first strand of the nth molecule and the even-numbered 
residues of the second strand of the (n -1)th molecule. These antiparallel sheets are 
held together by hydrogen bonds. All fibrils have been shown to form a left-handed 
helix [68,69]. 
Figure 1.5 Model of amyloid protofilament structure [61]. 
Figure 1.6 Model of a mature amyloid fibril [61]. 
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Fibrils formed by Abeta40 and Abeta42 appear to have a similar structure on a 
molecular level [70]. However, fibrillar structure has been shown to differ when the 
fibrils are grown in different solutions [71]. Furthermore, the conformation of the less 
structured N-terminus of the monomer can alter the fibril structure even though the -
sheet motif remains intact [70]. 
In the past, amyloid fibrils were believed to be structures of beta sheets arranged in an 
antiparallel conformation. As a result of NMR spectra reported within the last 10 
years, such opinion has shifted and a prevailing consensus has slowly emerged that 
the majority of Abeta fibrils are in fact stacked in a parallel conformation in most 
naturally occurring fibrils [66], though solid state NMR has shown anti-parallel β-
sheet stacking under certain conditions in vitro [67]. 
Stacking of Abeta peptides into amyloid fibrils can be anti-parallel, made up of 
parallel dimers or parallel stacks of anti-parallel dimers [66]. A parallel -sheet 
structure forms a linear chain with internuclear distance of approximately 4.8Ǻ. In an 
antiparallel β-sheet structure, a planar zigzag pattern would emerge with internuclear 
distances exceeding 4.8Ǻ. Tycko and colleagues compared fibrils formed from 
antiparallel -sheets and fibrils formed from parallel b-sheets and found that 
antiparallel sheets nucleate faster and are metastable with respect to parallel structure 
conversion. Both are equally neurotoxic [72]. 
Parallel structures are more stable than antiparallel structures because they have more 
ordered residues, longer beta strand segments and possible better packing of 
hydrophobic side chains [72]. Antiparallel fibrils are thermodynamically metastable. 
Antiparallel structures eventually evolve towards parallel structures when grown 
together with parallel fibrils. If the rate of spontaneous nucleation of antiparallel 
structure is greater than the rate of spontaneous nucleation of parallel structures, 
antiparallel conformations will dominate leading to a greater proportion of relatively 
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short antiparallel fibrils [72]. These fibrils will eventually shrink and disappear, as 
monomers become more stable antiparallel fibrils.  
Very recently, two different solid state NMR model of Abeta42 parallel fibrils came 
out, probably representing two different morphologies. One model shows a unique 
triple-β motif, which is made of three β-sheets encompassing residues 12–18, 24–33  
and 36–40 [73]. The second model shows instead  an S shape formed by four beta 
sheet with residues 15−42 comprising the amyloid fibril core and residues 1−14 
appearing to be unstructured and the basic subunit of the mature fibrils exists as a 
dimer (figure 1.7) [62]. 
 
  
Figure 1.7 Ribbon representation of the S shape tertiary structure of Abeta42 fibril core[62]. 
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1.3.4 Abeta peptides membrane interaction 
The C-terminal end of Abeta peptides is part of the transmembrane domain of APP, 
and therefore the soluble peptide may retain affinity for the cellular membrane or 
certain features of the membrane. A potential cytotoxic mechanism involving the 
cytoplasmic membranes was suggested. Monomeric Abeta42 has been shown to 
tightly insert into membranes, with a small portion being peripherally associated with 
lysosomal membranes, leading to their destabilization and induction of toxicity [74]. 
Moreover, the amphipathic nature of amyloid oligomers has been suggested to 
contribute to their capacity to penetrate and insert into membranes, coat or lie on the 
surface of the membranes, or potentially act as cell-penetrating peptides [16,75]. 
Moreover, has been shown that lipid membranes are able to act as template for Abeta 
peptides aggregation [76], but it can also dissolve preformed amyloid fibrils into more 
toxic oligomers [77]. The importance of the membrane interaction in the Abeta 
peptides toxicity mechanism is widely accepted in the literature, but in vitro the effect 
of this interaction dramatically depends on membrane composition and experimental 
conditions. 
To investigate the effect of membrane interaction on Abeta peptides aggregation, 
often simple, one-lipid species vesicles were used. It was demonstrated that in 
presence of neutral phosphatidylcholine vesicles, the lag time of Abeta40 aggregation 
was delayed and the half-time increased by 30%, dependent on lipid concentration 
[78]. Nucleation and elongation were also influenced by the presence of neutral lipid 
surfaces, and appeared to decrease when lipids were incubated with Abeta40. 
Secondary structural changes in Abeta conformation as a consequence of interaction 
with lipids have been demonstrated by CD spectroscopy [79]. The presence of various 
lipids, including egg yolk phosphatidylglycerol, bovine brain phosphatidylserine and 
phosphatidylethanolamine, induced the appearance of a strong 218 nm CD minima 
indicative of -sheet structure. It was suggested that the headgroup charge of the 
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phospholipids contributes to the association between Abeta40 and the membrane via 
electrostatic interactions. The affinity of Abeta40 to the zwitterionic 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC) was found to be weaker than for the 
anionic 1-palmitoyl- 2-oleoyl-sn-glycero-3-phospho-rac-(1-glycerol) (POPG) [80], 
supporting the view that the headgroup charges mediate binding. Moreover, although 
POPC binding did not result in aggregation of the Abeta40, POPG liposomes 
significantly increased aggregation. The surface charge and hydrophobicity of the 
membranes can modulate the binding of the peptide to the membrane surface. Abeta40 
preferentially binds to negatively charged phosphatidylglycerol membranes and 
composite membranes containing negatively charged lipids. On the other hand, the 
affinity between fibrillar Abeta40 and negatively charged membranes is lower with 
respect to neutrally charged membranes. The electrostatic forces were found to be 
more significant between monomeric Abeta40 and membranes, although hydrophobic 
forces were considered more important between fibrillar Abeta40 and membranes 
[81]. 
AFM studies have been used to monitor the assembly of Abeta42 on lipid bilayers 
composed of brain total extract, which provides a physiologically relevant ratio of 
acidic and neutral phospholipids. Small aggregates, about 5–7 nm in height, were 
initially found associated with the membrane and, after 7 h of in situ incubation, 
aggregates of about 5–15 nm in height were observed. Interestingly, this preparation 
of Abeta42 did not appear to ‘grow’ on the membrane bilayer [82]. To investigate the 
possibility that Abeta42 could form ion channels, it was incorporated into planar 
bilayers. AFM revealed multimeric complexes protruding above the lipid bilayer. The 
individual channels showed varying numbers of Abeta subunits, ranging from a two 
subunit arrangement to rectangular four subunit structures and hexagonal six subunit 
structures [36]. Electrophysiological records supported the view that Abeta42 was 
creating channels that allowed the passage of calcium ions [36]. By contrast to the 
conclusion that Abeta42 is able to form pores, was shown that size exclusion 
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chromatography-purified oligomers caused an increased conductance across mixed-
lipid bilayers in a concentration-dependent manner [83]. The results showed that 
conductance was nonselective for different ions and was inconsistent with specific 
pore formation. Further studies indicated that Abeta42 caused increased conductance 
by interacting with the membrane surface, possibly by spreading the lipid headgroups 
apart, leading to membrane thinning, and thus lowering the membrane dielectric 
barrier and increasing conductance [84]. 
Studies using lipid vesicles encapsulating self-quenching fluorescent dyes such as 
calcein and fluorescein have been used to study the effect of Abeta assembly on 
membrane integrity. The addition of Abeta42 to 1,2-dimyristoyl-sn-glycero-3-
phosphocholine large unilamellar lipid vesicles (LUVs) encapsulating calcein 
demonstrated that early oligomeric soluble species cause permeation of the 
membranes and the release of the encapsulated fluorescent dye [85]. It was also 
demonstrated that, as the Abeta42 peptide assembles into fibres in solution, the 
propensity to cause membrane permeation decreases, and mature fibres show a lack 
of ability to cause permeation. Interestingly, early oligomeric Abeta42 added to the 
vesicles elongates to form amyloid fibrils that appear to be associated with the 
membranes on EM [85]. This was suggested to cause mechanical disruption of the 
lipid membrane because of the growth of amyloid fibrils on membrane surface [86]. 
Moreover, it was suggested that Abeta42 is able to influence the cohesion of the 
components of the membranes [87]. 
In AD, the cholesterol content of certain regions of the brain can be markedly different 
from the same regions in non-demented brains; in particular, the cholesterol content 
is reduced by about 33% [88]. This reduction could significantly affect the fluidity of 
the neuronal membranes and make them more susceptible to Abeta peptides-induced 
permeation. Moreover, the decrease in cholesterol ⁄ phospholipid ratio in AD brains 
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may affect the cleavage of APP and cause an elevation in generated Abeta peptides 
[89]. 
The cholesterol content of membranes may play a role in modulating Abeta peptides 
penetration, because > 20% w⁄w cholesterol induces a membrane transition from a 
liquid-disordered (ld) to liquid-ordered phase (lo). As example, the Abeta fragment 
25–35 is unable to intercalate into the membrane bilayer in presence of cholesterol 
[90]. However, it was shown that Abeta40 spontaneously inserts into monolayers 
containing a 30% mol/mol cholesterol to phospholipid ratio and, in this context, 
adopts an -helical structure. Below this molar ratio, Abeta40 prefers to associate with 
the membrane surface region with a greater -sheet content [91].  
The cholesterol to phospholipid ratio has been reported to affect the affinity of Abeta 
peptides binding to synthetic lipid membranes. It was suggested that this increase in 
peptide-membrane affinity was a result of the involvement of cholesterol in altering 
membrane fluidity and structure [92]. Oligomeric, but not monomeric, Abeta42 was 
shown to insert into POPC⁄cholesterol membranes. Oligomer insertion was also found 
to occur in negatively-charged monolayers but not in the absence of cholesterol [93].  
The inclusion of < 30% mol/mol cholesterol in POPC membranes gave rise to channel 
activity induced by the addition of Abeta40, whereas no channel activity was observed 
in membranes containing only POPC [94]. It was suggested that cholesterol-rich 
membranes prevented the fibrillization of Abeta40 by increasing the incorporation of 
the peptide within the phospholipid bilayer [95]. 
Another key feature of Abeta peptides and membranes interaction is the preferential 
binding with Gangliosides. Gangliosides are a group of glycosphingolipids composed 
of a hydrophilic sialic acid terminal sugar exposed to the external environment and a 
hydrophobic ceramide moiety that is embedded within the membrane [96]. 
Gangliosides are involved in a variety of cell functions, including as cell type-specific 
markers, as differentiation and developmental markers, and as receptors and 
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mediators of cell adhesion [97], and they comprise 5–10% of the outer membrane 
leaflet [98]. The affinity between gangliosides and Abeta peptides can vary, but is in 
the micromolar range for the most common gangliosides present in the membranes; 
the highest affinity is toward the monosialic ganglioside GM1 [99]. The presence of 
gangliosides within the membrane bilayer induces structural transitions in Abeta 
peptides. Upon dilution of Abeta peptides in aqueous environment, they initially adopt 
a random coil structure but, upon the interaction with GM1, the peptides undergo a 
transition into a mixed / conformation at pH 7 and into a  conformation at pH 6 
[100]. Moreover, it was shown that neither the ceramide, nor sialic acid moieties could 
induce the structural transitions of Abeta peptides alone, implying that the association 
with the carbohydrate backbone and sialic acid is critical to induce structural 
transitions to Abeta peptides [100]. Fibrillization studies of Abeta40 in the presence 
of GM1 in the membrane showed that GM1 speeds up this process [101]. Electrostatic 
interactions may play a pivotal role in mediating Abeta–GM1 interactions (Abeta 
peptides are slightly positively charged and the GM1 headgroup is negatively 
charged); increasing the pH to 7.2 (where the peptides are negatively charged) leads 
to a decrease in peptides insertion because the interaction becomes repulsive [98]. The 
interaction with gangliosides-clustered domains is also important in this complex 
scenario [102].  
From the body of data present in literature, a model of Abeta peptides interaction with 
gangliosides have been proposed: when gangliosides are uniformly distributed on 
membranes, the protein remains soluble and does not interact with membranes. Once 
a ganglioside cluster is generated due to a high cholesterol concentration in 
membrane, Abeta peptides specifically bind to it. After binding, they undergoe a 
conformational transition from an α-helix-rich structure to a β-sheet-rich one with 
increasing protein density on the membrane. The β-sheet form serves as a seed for the 
formation of amyloid cytotoxic fibrils [103,104].  A schematic representation of this 
model is shown in figure 1.8. 
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From this huge amount of data present on Abeta peptides/liposomes interaction briefly 
summarized here, three structurally different models of membrane-mediated toxicity 
have been proposed for Abeta: the carpeting model; the ion channel model; the 
detergent model, all shown in figure 1.9. In carpeting model, Abeta peptides 
accumulate on one leaflet of the membrane surface, resulting in an asymmetric 
pressure between the two leaflets and leakage of small molecules [105]. This model 
is believed to be of minor physiological relevance for amyloid diseases because it is 
strictly related to the formation of amyloid fibrils, and doesn’t take in account the 
toxicity of soluble Abeta oligomers [86]. The formation of stable pores and ion 
channels is the second model proposed for amyloid-induced toxicity. The disruption 
of Ca2+ homeostasis has been recognized as a potential toxic mechanism associated 
with AD, and was shown to be involved in the amyloid cascade hypothesis, where 
elevated Ca2+ was suggested to be a consequence of both tau-phosphorylation and cell 
death [44]. The formation of Ca2+ channels in lipid bilayers was proposed in AD 
cytotoxicity because the incorporation of Abeta40 into planar phosphatidylserine 
bilayers formed channels that generated linear current–voltage relationships in 
symmetrical solutions [106,107]. Computational modelling of Abeta42 insertion into 
a lipid bilayer that approximately matches the thickness of 1,2-dioleoyl-sn-glycero-3-
Figure 1.8 Schematic representation of Abeta peptides interaction with gangliosides cluster. 
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phosphocholine bilayers showed that the transmembrane pore is formed by six 
hexamers, which span the bilayer and merge to form a more stable 36-stranded -
barrel arrangement [108]. This model is the most accepted because the parallel -
barrels formed by the N-terminal segments of the peptide form the lining of the pores 
and could account for the cationic selectivity observed for metal ions such as Zn2+ 
[109]. The third proposed model is based on the detergent-like effects of amyloid-
forming peptides on lipid membranes. This mechanism of permeation is proposed to 
occur through the membrane association of the peptides in the form of micelle-like 
structures. Membrane permeation occurs at high local concentrations of the peptide 
on the membrane surface, either after the surface is covered with peptide monomers 
or oligomers, or through the association between membrane-bound amyloid [110]. 
The initial interaction is electrostatically driven, because the peptide preferentially 
binds to either the phospholipid headgroup or receptors on the membrane surface, then 
it aligns with the hydrophilic surface facing the phospholipid head groups. The peptide 
hydrophobic residues are buried inside the hydrophobic core of the membrane, and 
this is followed by disintegration of the membrane by disruption of the bilayer 
curvature. The detergent effect results from the surfactant-like properties associated 
with the amphiphilic peptide causing a reduction in membrane surface tension, where 
it forms a hole by the removal of lipid from the bilayer [105].  
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The toxicity associated with Abeta peptides may not correspond exclusively to a 
single mechanism but more likely to an interplay of these mechanisms. Each 
mechanism may be involved in the disruption of biological membranes, either at a 
particular stage during the assembly of the amyloid-forming peptide or during a 
particular pathway taken during the peptide fibrillization.  
1.3.5 Glycation 
The term Glycation is referred in the recent literature as covalent, non-enzymatic 
modification of proteins by saccharides, well distinguished from the equivalent 
enzymatic reaction, called glycosylation [111]. Protein glycation involves the non-
enzymatic reaction of a reducing sugar or sugar derivative with a protein. The reaction 
needs a free carbonyl function to be carried out; no sugars that has aldehyde or ketone 
Figure 1-9 Possible Abeta peptides membrane-disrupting mechanisms. 
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groups converted to stable ketal and acetal groups of glycosidic bonds are able to give 
this kind of reaction. The linking sites between the sugar and proteins are proteins 
nucleophilic sites, lysines and arginines side chains and N-terminal amine. In addition, 
cysteine side chains could be affected. Glycation of proteins occurs by a complex 
series of sequential and parallel reactions collectively called the Maillard reaction 
[112]. Many different adducts may be formed, some of which are fluorescent and 
coloured ‘‘browning pigments’’. 
Several studies have shown that glycation stabilizes and promotes the formation of 
aggregated forms of proteins centrally involved in AD, such as Abeta and tau [113-
115]. Plaques extracted from AD brains contained 3-fold more glycated proteins than 
preparations from healthy, age-matched controls [116]. Therefore, glycation may be 
responsible for the increase in the crosslinking of these proteins and consequent 
formation of stable oligomeric forms. In the case of AD, glycation not only directly 
modulates the aggregation of these proteins, but also up regulates the expression of 
APP, increasing the levels of Abeta42 [117]. Strikingly, there is an age- and stage-
dependent accumulation of glycated products in AD brains. Glycated proteins levels 
in the cerebrospinal fluid of AD patients are increased and might constitute promising 
biomarkers for this disease [118]. To better understand the specific role of glycation 
in AD, the toxicity of normal and glycated Abeta peptides was evaluated in primary 
hippocampal neurons. The hypothesis that glycation exacerbates the toxicity of Abeta 
was confirmed, indicating that this kind of modification plays a role in Abeta toxicity 
mechanism [119]. 
The study of proteins modifications induced by glycation reaction is a topic relative 
new in proteins research. The reaction between lysine side chain and N-terminal 
amino groups by glucose was the major glycation process studied in the earlier 
literature. For this reason, the reaction was classified into two steps, early and 
advanced glycation processes. Glucose reacts with amino groups to initially form a 
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glycosylamine, which dehydrates to form a Schiff’s base. The Schiff’s base undergoes 
an Amadori rearrangement to form N-(1-deoxy-D-fructos-1-yl)amino acids or 
fructosamine [112]. This reaction stage is considered the early glycation process. 
Glycosylamine, Schiff’s base and fructosamines are considered to be early stage 
glycation adducts. In later reaction steps, fructosamine is degraded and forming many 
stable end-stage adducts called advanced glycation end products (AGEs) [120]. 
However, this classification fails when unattached glucose is  converted in reactive -
oxoaldehydes, which are potent glycating agents and react with proteins to form AGEs 
directly. The Schiff’s base adduct may also react via non-Amadori rearrangement 
reaction pathways to -oxoaldehydes which also leads to the formation of AGEs. 
Moreover, these reactive -oxoaldehydes can be formed also by the degradation of 
glycolytic intermediates and lipid peroxidation. A scheme of the reaction is shown in 
figure 1.10. 
 
 
Figure 1.10 Scheme of the possible glycation events [121]. 
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Important -oxoaldehyde or dicarbonyl glycating agents are glyoxal, methyglyoxal 
(MGO), and 3-deoxyglucosone, shown in figure 1.11. In the physiological setting, one 
of the important saccharides participating in glycation of mammalian metabolism is 
glucose, and some of the most important saccharide derivatives are the reactive 
dicarbonyl metabolites such as MGO. 
 
Another classification of glycation products has been made related to the mechanism 
of AGE formation. Glycoxidation is a term widely used for glycation processes in 
which oxidation is involved and the AGEs thereby formed have been called 
glycoxidation products [122]. The AGEs pentosidine and carboxylmethylysine are 
examples of glycoxidation products. Where aldehyde substrates of glycation are 
formed by lipid peroxidation, the end-stage adducts have been called advanced 
lipoxidation adducts. In figure 1.12 some possible glycation product are shown. 
Figure 1.11 Common glycation agents in physiological environment. 
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Protein glycation causes low-level endogenous damage to the proteome, modifying 
protein properties in unpredictable ways [123]. The enzymatic defence against 
glycation consists of enzymes that repair early glycated proteins and prevent glycation 
by metabolising dicarbonyl glycating agents: fructosamine 3-kinase [124], 
fructosamine 3-kinase-related protein [125]; and aldoketo reductases 1A4, 1B1 and 
1B3 [126]. The imbalance of glycating agents and enzymatic defence against 
glycation in favour of glycating agents has been termed carbonyl stress and is thought 
Figure 1-12 Possible glycation products. a Early glycation adducts formed by glycation with 
glucose: fructosamines. R indicates the amino acid side chain. b–f Advanced glycation endproducts. 
b Hydroimidazolones. c Monolysine adducts. d Imidazolium and other crosslinks. e Fluorophores. f 
Other Structures. 
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to contribute to ageing and disease [127]. By a clinical point of view,  formation and 
steady state accumulation of glycated proteins have been linked to disease 
development and progression, particularly diabetes and its vascular complications 
[128], renal failure [129], cardiovascular disease, Alzheimer’s disease [130,131], 
mood affective disorders such as anxiety and Schizophrenia [132], Parkinson’s 
disease [133] and other diseases are emerging. 
Recently, type 2 diabetes mellitus has been identified as an important risk factor for 
AD, increasing the risk  up to 60% [134]. Interestingly, both AD and diabetes lead to 
a desensitization of insulin receptors in the brain [135]. This causes not only glucose 
homeostasis impairment, but also impairment of the neuroprotective actions of 
insulin, facilitating the development of AD. Remarkably, administration of insulin to 
AD patients improves the ratio of Abeta40/Abeta42 (marker of decreased toxicity), 
enhances cortical activation, and improves performance in cognitive tasks [136]. 
Moreover, diabetes drugs reduce the formation of Abeta plaques and brain 
inflammation. In a triple transgenic mouse model of AD, a high-sucrose diet that 
induces several metabolic alterations found in diabetes is responsible for a significant 
increase in Abeta peptides levels [137]. This evidence further supports an important 
interplay between diabetes and AD. These findings highlight the importance of 
glycation in the context of AD.  
1.4 Hemopressin 
Hemopressin is a nonapeptide derived from hemoglobin -chain able to interact with 
cannabinoid CB1 receptor [138]. It was first isolated from rat brain homogenates in 
the 2003 [139].  
This peptide acts a CB1 receptor endogenous inverse agonist, and exerts 
antinociceptive, hypotensive and anoretic activity in rat and mice models [140,141]. 
It shows a similar binding affinity and the same binding pocket of rimonabant, a well-
known CB1 ligand [138,142]. Before the discovery of this peptide, the cannabinoid 
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receptor ligands were previously thought to be small and lipophilic molecules. 
Therefore, the finding of a peptide modulator of the cannabinoid receptor sparked 
interest for pharmaceutical development based on a hemopressin scaffold. 
N-terminally extended isoforms of hemopressin, RVD-hemopressin and VD-
hemopressin, were identified and reported to be CB1 agonists [143]. Only two or three 
residues are different between these peptides, but this difference appears to determine 
whether the hemopressin peptides exhibit antagonistic or agonistic activity, eliciting 
opposite effects at the CB1 receptor. Is still unclear whether hemopressin is an 
endogenous peptide or instead a cleavage product of the longer RVD-hemopressin 
peptide. The Asp-Pro peptide bond is one of the most labile bonds, especially under 
acidic conditions [144], which were used in the extraction of rat brains when 
hemopressin was originally identified. Indeed, a subsequent mass spectrometry study 
of mouse brain extracts under not acidic conditions did not identify hemopressin but 
instead only found the N-terminally extended peptides amongst others. The sequence 
of RVD-hemopressin is shown within the hemoglobin -chain sequence in figure 
1.13.  
 
Figure 1.13 Hemopressin sequence highlighted in the hemoglobin -chain sequence. PDB code 
2M6Z. 
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Unfortunately, works using hemopressin in obesity and pain therapy has been 
hampered by the lack of reproducibility associated to its usage in pharmacological 
assays [143]. In certain conditions (1 mM peptide in 25 mM phosphate, 50 mM NaCl, 
pH 7.4), hemopressin is able to self-assembly into amyloid like nanostructured fibrils 
[18], which may contribute to its inconsistent activity. Moreover, no fibrillation was 
observed in RVD-hemopressin at the same concentration, underscoring the unique 
ability of hemopressin to form fibrils, shown in Figure 1.14. 
 
Although the high peptide concentrations in these experiments may not be considered 
physiologically relevant, they are certainly pharmacologically relevant; high 
concentrations of peptide are generated during peptide synthesis, purification, and are 
used in peptide formulations and pharmacological assays as stock concentration. 
Because hemopressin is a naturally occurring peptide found within the brain, a better 
understanding of the physiological role of its self-assembly is needed. The distinct 
differences in aggregation properties and in the biological activity between these 
peptides suggest that the three additional residues, RVD, cause structural differences 
Figure 1.14 TEM images of Hemopressin (Panel A) and RVD-Hemopressin (Panel B) in 25 mM 
phosphate, 50 mM NaCl, pH 7.4 [18]. 
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or ionic interactions that prevent fibril formation and change the interaction with the 
CB1 receptor. To the best of my knowledge, very few information on hemopressin 
peptides conformation are available in literature. Comparing the conformation 
assumed by hemopressin peptides in their monomeric form would be helpful to 
understand the different aggregation propensities of the two peptides. 
1.5 Sweet Proteins 
Sugars or small non-caloric sweeteners are the classes of molecules commonly 
associated to the sweet taste, but also some proteins can exhibit this kind of property. 
Some of them are indeed intensely sweet, orders of magnitude sweeter than sugar 
[145]. Proteins that exhibit this kind of property are found in unrelated tropical plants 
and, apart from the origin, they have no functional, sequence or three-dimensional 
structure similarity [146]. They are able to interact with the same receptor that binds 
small sweet molecules, called human taste receptor T1R2-T1R3, a heterodimeric G-
protein coupled receptor located on specialised cells on the tongue [147,148]. To date, 
about ten sweet or sweet taste-modifying proteins were identified. Among them, the 
most known and studied proteins are: monellin [149], thaumatin [150], brazzein [151], 
miraculin [152].  Monellin, isolated from the African plant Dioscoreophyllum 
cumminsii, is one of the most potent sweeteners known, being about 90,000 times 
sweeter than sucrose on a molar basis [145]. Monellin is formed by two separate 
peptide chains that fold in a single domain through non-covalent interactions [149]. It 
shows an  architecture with a cystatin-like fold, with one helix that is embraced in 
a coiled antiparallel -sheet [153]. Due to the similar folding, monellin is considered 
a member of the cystatin superfamily [154], even if it didn’t show any protease 
inhibitory function. This protein is also a widely used model for protein folding studies 
[155]. 
Monellin chains dissociate when heated above 50 °C, when the protein loses 
sweetness as well, a clear indication that the correct folding is a prerequisite for 
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sweetness. Single chain constructs were engineered in order to overcome the low 
thermal stability. One of these, obtained by joining the two chains by the insertion of 
a Gly-Phe dipeptide linker, is called MNEI. This protein retains the sweetness and the 
same three-dimensional architecture (Figure 1.15) of the parent protein, but shows a 
greatly increased thermal stability [156]. 
 
Moreover, based on a hypothesis of the interaction between sweet proteins and the 
receptor called “wedge model” [157], even sweeter mutant of MNEI were designed, 
such as the single point mutant Y65R-MNEI [158,159]. 
Both native double chain monellin and MNEI are able to form amyloid fibrils after an 
initial denaturation event, i.e. when incubated at very high temperature [19,160]. So 
far, amyloid fibrils were never detected for the other MNEI mutants, such as Y65R-
MNEI. During food processing, extreme temperature and pH conditions are often 
used; these conditions could trigger sweet proteins aggregation, hampering their 
biotechnological application in food industry. 
 
Figure 1.15 Molecular model of MNEI, pdb code 1fa3. 
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1.6 Thesis outline 
In this thesis, the effect of different environments on the amyloid aggregation process 
of three molecular models (Abeta peptides, hemopressin and sweet protein Y65R-
MNEI) was studied by an integrated biophysical experimental approach. Considering 
the body of data already published on the amyloid fibril formation process, different 
aspects were studied for each molecule, therefore using different techniques. This 
approach allowed studying the amyloid aggregation process from different points of 
view. The results will be presented, divided by the topic, as follows: 
 In chapter 2, an expression and purification protocol for production of 
recombinant Abeta peptides Abeta40 and Abeta42 in E.Coli is presented; 
Abeta40 peptide obtained in such a way were used for the experiments 
presented in chapter 4. 
 In chapter 3, the interaction between Abeta42 and biomimetic lipid vesicles 
was investigated. The effect of this interaction was studied by different 
techniques: the changes in Abeta42 conformation upon interaction with the 
lipids were studied by CD spectroscopy, a very useful technique to investigate 
proteins secondary structure. On the other hand, changes in bilayers 
microstructure upon interaction with the peptide were studied by Electron Spin 
Resonance (ESR), using in particular the spin labelling approach; in this way, 
local information about fluidity changes in both hydrophilic polar head and 
hydrophobic lipid tail regions were obtained. Moreover, membrane 
permeabilization induced by monomeric Abeta42 was studied by a 
fluorescence based content-mixing assay, designed to investigate this kind of 
activity. 
 In chapter 4, the effect of a non-enzymatic post-translational modification, i.e. 
glycation reaction, on the structure and the aggregation properties of Abeta40 
and Abeta42 was studied. This reaction leads to the formation of a fluorescent 
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product, which was exploited to follow the reaction kinetic by fluorescence 
spectroscopy. Changes in peptide structure and aggregation properties caused 
by these modifications were studied by respectively CD and ThT binding 
fluorescence assay. ThT is a fluorophore able to selectively bind cross -sheet 
structures; this binding leads to changes in ThT spectroscopic properties, 
which can be followed to study amyloid fibril formation kinetics. 
 In chapter 5, the effect of pH and solvent polarity on hemopressin and RVD-
hemopressin conformation was studied. An initial condition screening was 
performed by CD, followed by a high-resolution structural analysis performed 
by bi-dimensional NMR spectroscopy. Particular attention was paid in 
comparing the conformation assumed by hemopressin peptides in each 
condition, in order to understand the different aggregation propensities of the 
two peptides. 
 In chapter 6, the effect of temperature, pH and ionic strength on the 
aggregation properties of the sweet protein Y65R-MNEI was investigated. 
Protein stability as a function of temperature was studied by CD thermal 
denaturation experiments. For each condition considered, the protein 
aggregation kinetics was investigated by ThT binding assay. The morphology 
of protein aggregates obtained in each condition was studied by AFM, one of 
the few techniques that can give a direct observation of protein aggregates 
shapes and dimensions. 
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Chapter 2 – Abeta peptides recombinant expression 
 
2.1 Work outline 
In this chapter it is reported a protocol for expression in E.Coli and purification of 
recombinant Abeta peptides. Despite decades of research about this topic, the 
production of these peptides is not yet an established routine, due to the high 
aggregation propensity of these peptides that makes them very tricky molecules to 
work with. The protocol I applied is based on an already published one [161]. 
The two plasmids expressing Abeta40 and Abeta42 peptides were gently provided by 
Professor Bernd Reif of Technical University of Munich. The peptides are expressed 
without any fusion protein and they have the N-term methionine, but is documented 
that this residue doesn’t change Abeta peptides structure and aggregation properties 
[161]. The peptides are isolated in the inclusion bodies from the bacteria hosts. Then, 
the purification protocol is made of three main steps: inclusion bodies purification, 
ion exchange chromatography and molecular mass fractionation, followed by dialysis 
and freeze-drying. The same protocol was used for both peptides, but was completely 
successful only for the shorter and more soluble peptide, Abeta40, presented in this 
chapter. 
2.2 Abeta40 expression and purification protocol 
The E.coli BL21 (DE3) strain was used for this expression. Competent cells were 
transformed with Abeta40 gene containing plasmid (pET28a), kanamycin resistant, 
confirmed by sequencing before the experiments.  
E.Coli cells growth and Abeta40 overexpression induction were performed using 
standard protocols; upon induction with IPTG, the cells were then harvested by 
centrifugation. 
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Due to Abeta40 exogenous nature and very high aggregation propensity, it is usually 
embedded in E.Coli inclusion bodies (IBs) when expressed as wild-type peptide, 
without any solubility-boosting tag attached to it [161]. Therefore, the first step of the 
purification protocol consists on IBs isolation and purification, performed by three 
sonication-centrifugation steps. At each step, proteins content was checked by SDS-
PAGE, shown in figure 2.1. In order to dissolve the purified IBs, a very high urea 
concentration (8 M) was necessary.  
The IBs solution was then diluted before the ion exchange chromatography. The 
separation was performed in batch, avoid the occurrence of local high concentration 
spots that could accelerate peptide aggregation, that hampers final peptide yield. A 
weak anion exchanger resin (DEAE) was used, and the peptide eluted by increasing 
stepwise the NaCl concentration. All fractions obtained were loaded on a SDS-PAGE 
(figure 2.1); the results indicate that the peptide is quite concentrated from 50 to 150 
mM NaCl buffers, and seems very pure. 
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In order to double check peptide purity, the fraction from 50 to 150 mM NaCl were 
concentrated 10-fold by filtration using a 3.5 kDa cutoff Vivaspin tube. Actually, 
some high molecular weight proteins (more than 10 kDa) were detected after fractions 
concentrations (data not shown). In order to get rid of them, all the collected fractions 
were filtrated in a second step through a 10 kDa cutoff Vivaspin concentrator, as also 
described by the reference paper [161]. 
Figure 2.1 SDS-PAGE of all Abeta40 purification steps; the fractions in which the peptide is more 
concentrated are the ones ranging from 50 to 150 mM NaCl. 
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Lane S: MW standards mixture. Lane A: 1° IBs wash. Lane B: 2° IBs wash. Lane C: 3° IBs 
wash. Lane D: dissolved IBs. Lane E: DEAE flow through. Lane F: 50 mM NaCl. 
Lane G: 75 mM NaCl. Lane H: 100 mM NaCl. Lane I: 125 mM NaCl. Lane J: 150 mM NaCl. 
Lane K: 200 mM NaCl. Lane L: 300 mM NaCl. Lane M: 500 mM NaCl. 
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After the MW fractionation step, the fractions from 50 to 150 mM NaCl were pooled 
and dialysed against ultrapure water using a 3.5 kDa cutoff dialysis tube overnight in 
order to desalt the peptide. The solution obtained was then freeze-dried, and peptide 
purity and identity was checked by spectroscopy (UV, CD) and mass spectrometry 
(figure 2.2). The final yield was 20 mg of Abeta40 per litre of culture. 
 
In conclusion, a good expression system and purification protocol were set up for 
Abeta40 recombinant production; the studies on glycation reaction effects on Abeta40 
aggregation properties reported in chapter 4 were performed using the recombinant 
peptide expressed by the protocol here described. On the other hand, some issues came 
out for Abeta42 expression. Even if the plasmid expressing for Abeta42 had the 
correct gene sequence, and the band position in the SDS-PAGE control experiment 
was coherent with the expected MW, it wasn’t detectable either by mass spectrometry 
Figure 2.2 Purified Abeta40 electrospray mass spectrum; the peaks corresponding to the double and 
triple ionized peptide are marked. Theoretical average mass: 4461 Da. 
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or NMR spectroscopy. Moreover, spectroscopic investigation gave very 
unreproducible and weird results.  Probably in this protocol Abeta42 co-purify with 
other non-proteinaceous impurities, which hampers its solubility in aqueous 
environment and its ionization efficiency, altering peptide biophysics properties. 
Henceforth in this thesis, all data regarding Abeta42 were obtained using a synthetized 
peptide sample produced by Professor Remo Guerrini of University of Ferrara [16]. 
2.3 Experimental Section 
2.3.1 Materials 
Plasmids (pET28a) containing genes expressing Abeta40 and Abeta42 were gently 
provided by Professor Bernd Reif of Technical University of Munich. Precasted 12% 
acrylamide gels were bought from Invitrogen (Carlsbad, California, USA). The ion 
exchange chromatography resin DEAE was bought from GE Healthcare (Little 
Chalfont, UK). Filtration systems and Vivaspin concentrator were bought from Merck 
(Darmstadt, Germany). All others laboratory reagents and solvents were bought from 
Sigma-Aldrich (Saint Louis, Missouri, USA). 
2.3.2 Transformation 
About 100 ng of plasmid DNA, containing the gene encoding for Abeta40 or Abeta42, 
were added to 100 l of competent cells (E.Coli BL21 DE3 strain) in ice, and they 
were incubated for 30 minutes. Subsequently, the cells membranes were closed by the 
thermic shock procedure, placing the cells in a 42 °C water bath for 30 seconds; 900 
ml of Luria-Bertani  broth (LB) without any antibiotic were added and the cells were 
growth at 37 °C under shaking for 45 minutes. The cells were harvested using a bench 
centrifuge and plated on previously prepared LB-Agar plate containing 0.1 mg/ml 
kanamycin, for correctly transformed colonies selection, and growth on the plate 
overnight at 37 °C.  
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2.3.3 Abeta peptides expression 
A single colony was picked from the LB-Agar plate and propagated overnight in 5 ml 
of LB containing 0.1 mg/ml kanamycin. 1 mL from this culture were diluted to 1 l of 
the same medium in a 4 l flask, and incubated at 37 °C under 200 rpm agitation, until 
the optical density at 600 nm (OD600nm) reached a value of 0.6/0.7. At this point, 
Abeta peptides production was induced by adding IPTG at the final concentration 1 
mM, and the culture incubated for four hours at the same temperature and agitation 
speed. The cells were then harvested by centrifugation at 5000 g for 30 minutes at 4 
°C, then the supernatant was discarded and the cell pellet frozen and stored at -80 °C. 
2.3.4 Inclusion bodies purification procedure 
The cells pellet was resuspended in 10 ml of Tris buffer 10 mM pH 8.0 containing 1 
mM EDTA (Buffer A) and sonicated for 2 minutes, at power output 5 and duty cicle 
50%, using an ultrasonic cells disruptor with a thin tip, taking the sample into an ice 
bath over the whole procedure. The suspension was centrifuged for 10 minutes at 
18000 g and 4 °C. The supernatant, after checking its protein content by SDS-PAGE 
electrophoresis, was discarded. This procedure was repeated three times in order to 
properly purify the IBs from other, more soluble E.Coli endogenous proteins. 10 ml 
of Buffer A containing 8 M Urea was added to completely dissolve IBs and the 
suspension was sonicated (using the same parameters already mentioned) until a clear 
solution was obtained. 
2.3.5. Ion exchange chromatography 
The IBs dissolved were then diluted with Buffer A containing 8 M Urea to 40 ml total 
volume for the ion exchange chromatography. 20 ml of weak anion exchanger resin 
(DEAE Sepharose) were extensively washed with ultrapure water, equilibrated with 
Buffer A containing 8 M Urea and mixed with the IBs solution. This suspension was 
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incubated, under gently agitation, for one hour, to allow peptides binding to the resin. 
Then the resin was recovered by gentle vacuum filtration using a Millipore 22 m 
filter. Abeta peptides were then eluted by increasing stepwise the NaCl concentration; 
in details, 20 ml of Buffer A containing 0, 50, 75, 100, 125, 150, 200, 300, 500 mM 
NaCl were subsequently added to the resin. After every buffer addition, the suspension 
was incubated for 5 minutes under gentle agitation at room temperature before 
collecting the buffer solution by vacuum filtration. All these operations were 
performed in cold room at 4 °C. 
2.3.6 MW fractionation step 
The peptide was separated from the high molecular weight (>10000 Da) contaminants 
by a MW fractionation step performed using Millipore Vivaspin concentrator with a 
membrane cutoff of 10 kDa at 4000 rpm and 4 °C. The same procedure was used to 
concentrate the fractions before the SDS-PAGE experiment as well, but a different 
membrane cutoff (3.5 kDa) was used in this case. 
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Chapter 3 - Interaction between Abeta42 with model 
phospholipid bilayers 
 
3.1 Work outline 
Many experimental evidences indicate that the interactions with neuronal membranes 
play an important role in the Abeta42 toxicity [85,102], and the study of the 
interactions between Abeta peptides and membrane model systems is a very important 
topic in the recent literature, as discussed in more details in section 1.3.4.  
AD is also elicited by the interplay of genetic, environmental and dietary factors 
[162,163]. The adherence to a Mediterranean diet profile, including fish, vegetables, 
fruits, coffee, and light-to-moderate alcohol intake, seems to reduce the incidence of 
this and other neurodegenerative pathologies [164]. The beneficial effects of fish are 
at least partially ascribed to the high content of polyunsaturated fatty acids (PUFA), 
and specifically of Omega-3 ones [165]. However, the effectiveness of these 
molecules is still controversial, and their mechanism of action remains elusive. 
Among other hypotheses, mainly based on the radical-scavenging and anti-
inflammatory action of PUFA [166,167], it has been proposed that Omega-3 fatty 
acids, once converted to lipids, could alter the structure and functionality of neuronal 
membranes, whose involvement in AD etiology is widely accepted [168]. 
Docosahexaenoic acid (DHA) is found in extraordinarily high concentration in the 
plasma membranes of neural tissues, reaching up to 50% of the total acyl chains 
[169,170], and its decline has been associated with the loss of memory and learning, 
suggesting that the Omega-3 fatty acids modulate the membranes properties and 
influence the molecular mechanism of AD [171,172].  Recently, it has been proposed 
that Omega-3 lipids disturb the lipid packing in the membrane, favouring a deeper 
internalization of Abeta fragments among the lipid acyl chains [173], offering a 
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possible explanation for the inhibition of Abeta self-aggregation operated by Omega-
3 fatty acids. 
To get light in this complex scenario, the interaction of Abeta42 with bilayers whose 
lipid composition reproduces the main components of neuronal membranes [174,175], 
including both zwitterionic and anionic phospholipids, cholesterol, sphingomyelin 
and gangliosides has been investigated. Moreover, the effect of the inclusion of the 
Omega-3 lipid 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine [22:6(cis)PC] in 
the bilayer composition is analysed in detail. 
An integrated experimental approach was applied for this study. The effect of complex 
lipid bilayers on Abeta42 conformation/self-aggregation was monitored by CD; the 
influence of Abeta42 interaction on the membrane microstructure and fluidity was 
studied by ESR measurements; the disrupting effect of this interaction on membrane 
integrity was studied by a previously established fluorescence-based membrane 
leakage assay.  
3.2 Sample conditions design 
Six different conditions were explored in this work, using always the same (20 M) 
Abeta42 concentration. Two control conditions were used: HFIP/NaP 20 mM  pH 7.4, 
80/20 % v/v, and 20 mM NaP pH 7.4, in order to check peptide behaviour in apolar 
environment a polar environment respectively. Four different liposomes composition 
were studied: 0.4 mg/ml of lipid bilayers formed only by palmytoil-oleil-
phosphocholine (POPC-LB); 0.4 mg/ml of neuronal membrane mimicking lipid 
bilayer (NML-LB), which includes zwitterionic and anionic phospholipids, 
cholesterol, sphingomyelin and gangliosides [175,176]; 0.4 mg/ml of NML-LB 
containing also 25% w/w of the unsaturated fatty acid 22:6(cis)PC (O3-LB); 0.4 
mg/ml of NML-LB containing 10% w/w of 22:6(cis)PC (O3L-LB). The two last 
mixtures were prepared with two different amounts of 22:6(cis)PC to evaluate its 
specific potential effect on Abeta42 solubility and structure. The detailed liposome 
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compositions are reported in the experimental section. The chemical structure of all 
lipids used for this study are reported in figure 3.1. 
 
3.3 CD spectroscopy 
In consequence of the generally low solubility of Abeta42 and fast aggregation in 
aqueous solutions, we have checked the peptide conformation in experimental 
conditions already known to induce canonical secondary structures in Abeta, i.e. 
HFIP/water mixture and phosphate buffer. Both the controls spectra gave the expected 
results, showing the typical shape of -helix and -sheet respectively, thus confirming 
the absence of pre-existing aggregates in the dry peptide film. Interestingly, in the 
presence of POPC-LB the spectrum of the peptide showed the shape of a -structure, 
though the minimum was shifted at a slightly higher wavelength, according to the 
presence of aggregated forms [77]. In contrast, in the presence of more complex lipid 
bilayers (NML-LB, O3-LB and O3L-LB), only a low intensity CD signal was detected 
Figure 3.1 Chemical structures of all lipids used in liposomes formulation. 
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and no regular secondary structure could be associated to the spectrum. The CD 
spectra of peptide upon dissolution in every condition are reported in figure 3.2.  
 
Since the kinetics of aggregation/dissolution processes and conformational transitions 
of Abeta42 are quite slow, the CD spectra of the peptide in the different conditions 
were monitored over several days. The results obtained are reported in Figure 3.3 for 
each liposome conditions. The control experiments, not shown in the figure, gave the 
expected results: the spectrum in HFIP/water mixture was unaffected over the whole 
incubation time [16]; on the other hand, when the peptide was dissolved in phosphate 
buffer, the signal intensity decreased over time, becoming almost undetectable after 
14 days, in agreement with the expected formation of insoluble aggregates in aqueous 
environments. 
 
Figure 3.2 CD spectra of Abeta42 just after dissolution in the conditions studied. 
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Figure 3.3 panel A shows that the shape and intensity of the spectra acquired in POPC-
LB over time were constant, suggesting that the soluble aggregate concentration does 
not change. However, the presence of insoluble, CD silent forms cannot be excluded. 
In the presence of NML-LB bilayers, the low intensity of the CD signal indicates that 
only a small fraction of the peptide was dissolved (panel B), and no significant 
increase is appreciated over time. Yet, the spectrum shape changes during the 
incubation time, confirming that the lipid bilayer is able to interact with the peptide 
[85]. Unlike the previous cases, in the lipid bilayer O3-LB, the peptide slowly but 
extensively dissolves after several days, as highlighted by a consistent increase in the 
CD spectrum intensity. The spectrum assumes a shape similar to that observed in the 
presence of POPC, except for a further red-shift of the minimum, suggesting the 
presence of higher size soluble aggregates. Interestingly, the time necessary to 
appreciate changes in the CD spectrum decreases when the amount of Omega-3 lipid 
present in the lipid mixture increases. Indeed, while the presence of higher 
concentration of 22:6(cis)PC  (panel D) induces the peptide film dissolution after 21 
Figure 3.3 CD spectra time evolution of Abeta42 interacting with different lipid bilayer:, POPC-LB 
(panel A); NML-LB (panel ); O3L-LB (panel C);  O3-LB (panel D). 
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days incubation, at lower 22:6(cis)PC concentration (panel C) the spectrum shape 
changes slightly during 28 days incubation, but no clear trend can be appreciated, as 
in the case of NML-LB. These evidences suggest the presence of membrane 
interacting peptide aggregates slowly evolving over time when Omega-3 lipids is 
added in the lipid bilayer formulation [77]. However, the kinetics of this process 
critically depends on the amount of Omega-3 present in the lipid phase. 
3.4 Electron Paramagnetic Resonance 
The changes in lipid ordering and dynamics were studied using the spin label 
approach. Two spin-labeled phosphocholines were used as reporter: 5-PCSL and 14-
PCSL. The former bears the radical in proximity of the polar head, just underneath 
the hydrophilic surface, while in the latter the label is close to the acyl chain terminus, 
thus spectra are representative of the inner apolar region behaviour. 
The spectra of 5- and 14-PCSL in POPC bilayers are reported in figure 3.4, 
respectively panel A and panel B (black lines). 14-PCSL generates an almost isotropic 
three-line spectrum. In contrast, a clearly defined anisotropy is observed for 5-PCSL, 
as highlighted by the splitting of the low- and high-field signals. Thus, the rotational 
motion of the label is hindered in the relatively ordered external region of the bilayer, 
while it is almost free in the bilayer interior. A quantitative analysis of the spectra was 
accomplished by determining the lipid segmental order parameter (S), as reported in 
the literature [177]. The S value is 0.64 for 5-PCSL and 0.14 for 14-PCSL. These 
evidences indicate that POPC-LB presents a marked rigidity and ordering decrease in 
going from the lipid polar head to the acyl tails termini, as expected for membranes in 
the liquid crystalline disordered state (Ld) [178]. In the case of the NML-LB, both 
spin-labelled lipids show anisotropic spectra (figure 3.4). The S value is 0.74 for 5-
PCSL and 0.41 for 14-PCSL, showing that these bilayers are more rigid than the 
previous ones, and the lipid ordering gradient in going from the polar head to the acyl 
tails termini is lower.  
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This indicates that NML-LB are in the liquid crystalline ordered state (Lo). Also in 
the presence of 22:6(cis)PC both spin-labelled lipids have anisotropic spectra; the two 
Omega3 containing lipid bilayers show the same lineshape, as example the spectra for 
the O3-LB mixture are shown in figure 3.4. No additional spectral component, 
evocative of domain formation [179], was detected. The rigidity of the membrane is 
only slightly reduced with respect to NML-LB even in the presence of the higher 
amount of Omega-3 lipids, as the S value is 0.68 for 5-PCSL and 0.38 for 14-PCSL. 
This indicates that inclusion of 22:6(cis)PC in the lipid mixture does not change the 
liquid crystalline organization of the bilayer, which remains in the Lo state. In a 
previous work was found that 22:6(cis)PC is able to drive the Lo/Ld transition in the 
case of a POPC/SM/Chol bilayer [173]. Moreover, Omega-3 lipid bearing two 
polyunsaturated acyl chains, like 22:6(cis)PC, are reported to drive the segregation of 
Chol, with formation of lipid domains [180,181]. The resistance of NML-LB to 
undergo any transition is probably ascribable to the presence of GM1, which is 
recognized as a major player in the modulation of later ordering within biological 
membranes [182], limiting domain growth. 
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The presence of Abeta42 in the system affects the POPC-LB organization [173,183], 
as revealed by the spectra of 5- and 14-PCSL registered soon after samples preparation 
(Figure 3.4, red lines). In the case of 5-PCSL a slight reduction of the spectrum 
anisotropy is observed, as confirmed by the decrease of the S value by ~0.02. An 
opposite behaviour is observed for 14-PCSL: the spectrum anisotropy increases and 
S raises by ~0.04. However, no evidence of a second component in the spectrum is 
observed, as expected for membrane-penetrating peptides. Thus, the experimental 
evidences point to a positioning of the peptide close to the membrane interface, 
causing perturbation in the lipid dynamic and ordering that propagates to the bilayer 
inner core. 
Even for NML-LB the presence of Abeta42 in the system causes a small reduction of 
the 5-PCSL spectrum anisotropy and a consequent slight S decrease of ~0.02. 
Figure 3.4 EPR spectra of the two spin reporter used in this study, 5-PCSL (panel A) and 14-PCSL 
(panel B) of the investigated liposome compositions. Black lines: EPR spectra of liposomes without 
Abeta42. Red lines: EPR spectra just after peptide addition. Cyan lines: EPR spectra after 21 days 
of incubation. 
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However, almost no variation is found in the 14-PCSL spectrum. These results 
indicate a weak interaction of the peptide with the membrane interface, which does 
not affect the inner bilayer structure. 
In the case of the Omega-3 lipid containing lipid bilayers, similarly to what observed 
for NML-LB, the presence of Abeta42 causes a reduction of the 5-PCSL spectrum 
anisotropy, as confirmed by the reduction of 0.02 in the S value, while no effect is 
registered for 14-PCSL. Thus, inclusion of 22:6(cis)PC does not affect peptide-
membrane interaction in just-prepared samples. 
The evolution over time of the 5- and 14-PCSL spectra in all the considered bilayers 
was followed both in the absence and in the presence of Abeta42. No spectra change 
was observed in the peptide absence. In the case of O3L-LB and O3-LB, this indicates 
that no 22:6(cis)PC oxidation occurs, in line with the long-term stability of Omega-3 
lipids in liposomes reported in the literature [184]. For samples containing the peptide, 
significant changes of the spectra with time were observed, depending on the bilayer 
lipid composition. In the case of POPC a progressive reduction of the 5-PCSL 
spectrum anisotropy is observed, as shown by the trend of S reported in figure 3.5. 
As an example, the spectra of the two spin labels in POPC-LB in the presence of the 
peptide after 21 days are shown in figure 3.4 (cyan lines). In contrast, the 14-PCSL S 
value remains almost constant (figure 3.5). 
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The 5-PCSL and 14-PCSL spectra in NML-LB exposed to Abeta42 remain almost 
unaltered, indicating that the weak interaction of the peptide with the membrane does 
not strengthen with time. 
In the presence of Omega-3 containing lipid bilayers, for both the formulations 
considered (O3L-LB and O3-LB), the 5-PCSL spectrum exposed to Abeta42 remains 
almost constant whilst, interestingly, in the case of 14-PCSL the spectrum anisotropy 
becomes markedly more evident after three weeks and, consequently, the S value 
significantly increases (figure 3.5). These results indicate an increasing membrane 
perturbation of the bilayer inner core due to the interaction with the peptide, 
modulated by the amount of Omega-3 lipids in the membrane, as it is elicited after a 
smaller time-lag for O3-LB than for O3L-LB systems. 
Internalization of Abeta fragments has been observed in the case of POPC/SM/Chol  
bilayers enriched in 22:6(cis)PC, which, differently from the ones used in this study, 
are in the Ld state [173]. This could indicate that the peptide selectively interacts with 
Omega-3 lipids, almost independently of the lipid bilayer state. 
Figure 3.5 Time course evolution of S for the spin label 5PCSL (panel A) and for 14PCSL (panel B) 
for each lipid bilayers studied when interacting with Abeta42. 
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3.5 Membrane Leakage 
The leakage activity of the peptide towards the lipid compositions investigated was 
studied by a fluorescence based content-mixing assay [185]. Liposomes loaded with 
a fluorophore, 8-Aminonaphthalene-1,3,6-Trisulfonic Acid (ANTS), and its 
quencher, p-Xylene-Bis-Pyridinium Bromide (DPX), were titrated with Abeta42. In 
case of pore formation upon liposomes-peptide interaction, the two molecules are 
released in the bulk solution, resulting in molecules detaching and ANTS dequenching 
effect. In order to study the leakage activity of Abeta42 in its monomeric form, the 
peptide was dissolved in DMSO; in this solvent, Abeta42 aggregation is hindered, and 
it assumes a random-coil conformation. The data, shown in figure 3.6, indicate a very 
strong permeabilization effect towards all the three liposomes composition studied, 
with high leakage activity even if very low peptide/lipid ratios were explored. Omega3 
lipid embedded in liposomes does not affect the Abeta42 leakage activity, that shows 
a similar permeabilization effect on both NML-LB and O3-LB. In case of POPC 
liposomes, pore formation by this interaction is clearly lower.  
 
Figure 3.6 Abeta42 leakage activity towards the studied lipid bilayers titration curves. 
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3.6 Conclusions 
In conclusion, by using CD spectroscopy, we have preliminarily verified that, in 
phosphate buffer and in the absence of lipids, the peptide adopts the expected  
conformation and undergo the subsequent self-aggregation forming insoluble 
aggregates. The effect of single-component lipid bilayer has been also investigated by 
using POPC, a zwitterionic phospholipid abundant in eukaryotic cells, often chosen 
for membrane-peptide interaction studies. These results show that POPC-LB stabilize 
for several weeks a soluble, aggregated form of Abeta42, having a small but constant 
concentration. The CD spectrum is indeed very reproducible over time, but has a low 
intensity and shows a shift of the  sheet minimum toward higher lambda values, 
which can be the effect of a  aggregated but soluble structure, with a scattering [186] 
due to the presence of high molecular weight aggregates. ESR results show that these 
aggregates interact with the membrane interface, increasingly disturbing its 
organization, while the bilayer interior is only indirectly affected. 
Interestingly, biomimetic lipid bilayers (NML-LB) do not present the ability to 
solubilize the peptide, although CD spectra suggest the presence of a small amount of 
peptide deprived of regular secondary structure also associated with the lipid phase. 
Our results indicate that, in the presence of GM1, large and likely heterogeneous 
aggregates interacting with the membrane interface quickly form. Furthermore, the 
experimental evidences clearly show that these insoluble aggregates are not able to 
penetrate in the lipid bilayer [187,188]. This could be connected with the rigidity of 
the lipid phase (in the Lo state), which in this case is much higher than that of POPC-
LB (in the Ld state). 
Inclusion of 22:6(cis)PC in the lipid composition does not affect the initial behavior 
of the membrane in the presence of Abeta42: only a limited perturbation of O3-LB 
interface is observed, probably due to a weak interaction with large, insoluble 
aggregates. However, CD data clearly show that, over time, an increasing fraction of 
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the peptide convert to soluble, lipid associated, aggregates, able to interact with the 
bilayer. The -sheet minimum indeed undergoes a further shift toward high 
wavelength with respect to POPC-LB, suggesting an increasing of the scattering 
contribution in the spectra. Furthermore, ESR spectra indicate that these aggregates 
are significantly embedded in the bilayer, differently from the superficial interaction 
in case of NML-LB, as schematised in figure 3.7. 
 
The comparison of the data obtained by introducing two different 22:6(cis)PC 
amounts in the lipid bilayer formulation indicates that qualitatively the effect of 
Omega-3 lipid presence is independent by the amount of this component, however the 
extent of the perturbation and the kinetics of the process are enhanced when the 
Omega-3 lipid concentration increases. It is to be highlighted that the dramatic 
enhancement of the Abeta42 affinity for the membrane due to 22:6(cis)PC cannot be 
straightforwardly related to changes of the bilayer properties, considering that this 
lipid causes only a slight reduction of the bilayer ordering. This result could induce to 
speculate about a peptide molecular preference for the Omega-3 lipid, which, 
however, should be better investigated. 
Figure 3.7 Scheme of the different interaction model proposed for Abeta42 and neuronal membrane 
biomimetic lipid bilayers (left side), and Omega3 containing biomimetic bilayers (right side). 
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3.7 Experimental Section 
3.7.1 Materials 
The Abeta42 peptide was synthesised as previously reported  [16]. The phospholipids 
POPC, POPS, SM, GM1 ovine brain sodium salt, 1,2-didocosahexaenoyl-sn-glycero-
3-phosphocholine (22:6(cis)PC) and spin-labelled phosphatidylcholines (n-PCSL) 
with the label at different positions (n) in the sn-2 acyl chain were purchased from 
Avanti Polar Lipids (Alabaster, Alabama, USA). Chol, HFIP, TFA, ANTS, DPX and 
other laboratory reagents were purchased from Sigma-Aldrich (St. Louis, Missouri, 
USA). 
3.7.2 Liposome preparation 
Large unilamellar vesicles (LUVs) consisting of POPC (POPC-LB, where LB stands 
for lipid bilayers), POPC/POPS/Chol/SM/GM1 (8/2/9/1/1 mol/mol, henceforth 
indicated as neuronal membrane-like lipid bilayers, NML-LB), 
POPC/POPS/Chol/SM/GM1/22:6(cis)PC (4/2/9/1/1/5mol/mol, henceforth indicated 
as O3-LB) and POPC/POPS/Chol/SM/GM1/Omega-3 (6/2/9/1/1/2mol/mol, 
henceforth indicated as O3L-LB,), were prepared in 20 mM phosphate buffer pH 7.4, 
freshly degassed by Nitrogen purging, at total concentration of 0.4 mg/ml. The organic 
film rehydration/extrusion method, previously described [173], was adopted. 
Sonication steps and direct exposure to light were systematically avoided to minimize 
the oxidation processes. For ESR investigation, 1% w/w of the spin-label was added 
to the lipid mixture in organic solvent before drying. 
3.7.3 Peptide samples preparation 
The Abeta42 peptide was pretreated with TFA, in order to dissolve any fibrillar 
aggregates, as previously described [16]. The sample was then freeze-dried and 
redissolved in pure HFIP, and then the UV and CD spectra were recorded to assess 
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the acid treatment success. This solution was divided in aliquots of 100 g each, and 
the solvent was dried under nitrogen flux to form a peptide film. These films were 
then rehydratated with 1 ml of 0.4 mg/ml liposome suspensions, yielding a 
lipid/peptide ratio of 25/1 mol/mol, and the samples were incubated at 4 °C as 
indicated and used for both CD and ESR experiments. 
3.7.4 CD spectroscopy 
CD spectra of Abeta42 (0.1 mg/ml final concentration) were taken using Jasco J-810 
spectropolarimeter (Jasco international Co. Ltd, Tokyo, Japan) in the range of 200–
260 nm using a 0.1 cm path length quartz cuvette at 20 °C in continuous scanning 
mode (20 nm/min, with a 4.0 s response and a 1.0 nm band width). Spectra 
corresponding only to the solvent or lipid bilayers in the absence of the peptide have 
been recorded thoroughly during the measurements and subtracted from the 
corresponding peptide/lipid bilayer spectrum. The data were accumulated over 3 runs, 
the presented data being the average. The results are expressed in term of molar 
ellipticity [], in unit of deg cm2/mol. 
3.7.5 ESR spectroscopy 
ESR spectra of lipid and lipid/peptide samples were recorded in collaboration with 
Prof. Gerardino D’Errico on a 9 GHz Bruker Elexys E-500 spectrometer 
(Rheinstetten, Germany) at 20 °C. Capillaries containing the samples were placed in 
a 4 mm quartz sample tube. The instrumental settings were: sweep width, 120 G; 
resolution, 1024 points; modulation frequency, 100 kHz; modulation amplitude, 1.0 
G; time constant, 20.5 ms, incident power, 5.0 mW. Several scans were accumulated 
to improve the signal-to-noise ratio. The quantitative analysis of the spectra was 
performed through a homemade, MATLAB-based software routine. 
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3.7.6 Leakage experiments 
The ANTS/DPX assay [189] was used to monitor leakage induced by peptide 
interaction with vesicles. The fluorescence signal resulting from the de-quenching of 
ANTS released into the medium was observed through a HORIBA Fluoromax-4 
spectrofluorimeter. The excitation wavelength was set to 360 nm, the emission 
wavelength red to 520 nm. The liposomes were titrated with a 1 mM Abeta42 solution 
in DMSO. The vesicles were completely lysed by the detergent Tween10, to obtain 
the maximal fluorescence value, which was set to 100% leakage. Fluorescence from 
intact vesicles in NaP 20 mM pH 7.4 buffer was set to 0% leakage, and results were 
normalized according to this scale. Liposomes were also titrated with the same 
volumes of NaP 20 mM pH 7.4 buffer and DMSO, in order to correct the dilution and 
DMSO effects. All experiments were repeated three times, and the average is reported. 
[185]. 
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Chapter 4: Effect of glycation on structure and aggregation 
properties of Abeta peptides 
 
4.1 Work outline 
The effects of the glycation reaction on biological and biophysical properties of 
peptides and proteins is a very hot topic in the recent literature. Glycation could have 
very different effect on protein aggregation properties; it could both increase (as 
example albumin) and decrease (as example lysozime) the amyloid formation rate, 
depending if it promotes the formation of either on- or off-pathway oligomers [123]. 
Nevertheless, the effect of glycation and AGEs formation on biophysical properties 
of Abeta peptides is an intriguing topic that has not yet been addressed. 
In this thesis, the effect of glycation reaction on structure and aggregation properties 
of Abeta peptides Abeta40 and Abeta42 was studied by an integrated combination of 
biophysical techniques. Methylglioxal (MGO), a three-carbon atom compound with 
two carbonyl function formed as a product of sugars autoxidation, was chosen as 
glycation agent. Its structure is shown in figure 4.1. MGO is too small to cyclise as 
other longer carbohydrates (such as glucose), leaving the carbonyl function always 
available for the reaction and therefore this compound shows a very high protein 
modification capacity, both in vitro and in vivo [190]. Both studied Abeta peptides 
have four possible glycation sites: the N-terminus, one arginine (5Arg) and two 
lysines (16Lys, 28Lys). 
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The reaction kinetic was studied by fluorescence spectroscopy, as one of the reaction 
product between MGO and arginine side chain, called argpyrimidine (see figure 1.13 
for the chemical structure) has an aromatic moiety that shows fluorescence when 
excited at 340 nm [191], thus it  can be exploited to follow the reaction progression. 
The effect on peptides secondary structure was studied by CD spectroscopy. Changes 
in the aggregation behaviour were monitored using the Thioflavin T (ThT) assay [9].  
As the Abeta peptides conformation and solubility are strongly affected by the solvent 
polarity [57], the reaction was carried out in two different conditions. The first 
condition is phosphate buffer 200 mM pH 7.4, in order to simulate a polar 
environment, in which the Abeta peptides quickly adopt a beta conformation, leading 
to peptide self-assembly; moreover, it is known that phosphate is able itself to catalyse 
the glycation reaction [192]. The second condition is a HFIP/NaP 200 mM pH 7.4 
mixture (80%/20% by volume), henceforth called HFIP mixture. This condition 
simulates a low polarity environment, in which even the most aggregation prone 
Abeta42 keeps a stable, soluble -helical structure, so the glycation and aggregation 
processes are decoupled in this condition. The reaction was carried out in all cases at 
37 °C, using a 100 fold molar excess of MGO. 
The Abeta peptides were pre-treated in strong acidic condition in order to dissolve 
any pre-existent aggregates, prior to each experiment. They were divided into two 
Figure 4.1 Methylglioxal chemical structure. 
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aliquots, and then dissolved at 100 M final concentration in NaP 200 mM pH 7.4 
(for more details, see experimental section), or at 50 M final concentration in the 
HFIP/buffer mixture. In one aliquot, MGO was added at 10 mM final concentration 
(100-fold excess). This sample will be called glycated Abeta (Abeta40G and 
Abeta42G). The other sample was instead incubated without MGO, as control of 
peptide behaviour in this condition, and called non-glycated Abeta (Abeta40NG and 
Abeta42NG). 
All experiments reported in this chapter were repeated three times. The spectra 
reported (both fluorescence and CD) are relative to one representative experiment. All 
reported kinetics are the average of all performed experiments. 
4.2 Aqueous environment 
4.2.1 Reaction kinetics 
Abeta40G shows a very strong fluorescence signal when excited at 340 nm just after 
one day of incubation at 37 °C, with the maximum centred at 400 nm. Some recorded 
fluorescence spectra are reported in figure 4.2, showing that the fluorescence 
intensity, and therefore the argpyrimidine concentration, reaches a plateau after about 
three days of incubation. The kinetics of the reaction is clearer when plotting 
normalised fluorescence intensity at emission maximum (400 nm) against time, as 
reported in figure 4.2. 
 Chapter 4: Effect of glycation on structure and aggregation properties of Abeta peptides  
62 
 
 
  
 
Figure 4.2 Fluorescence emission spectra of Abeta40G. 
 
Figure 4.3 Fluorescence intensity in correspondence of the emission maximum in function of time. 
When not visible the error bar is within the symbol. 
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Control experiments were performed on AbetaNG and MGO in phosphate buffer, 
revealing no significant fluorescence intensity upon excitation at 340 nm. In fact, also 
the incubated MGO shows fluorescence, even if at different wavelengths. In figure 
4.4, some excitation spectra of MGO are reported; they show a signal build up with 
time when excited at about 390 nm, probably due to some MGO self-polymerization 
adducts promoted by the high concentration.  The MGO and AGEs excitation 
wavelengths are very different; no interference should arise on AGEs fluorescence. 
 
The same experimental procedures were used to study the effect of glycation on the 
full-lenght amyloid peptide Abeta42. Also in this case, two aliquots were made, one 
with 10 mM MGO (Abeta42G) and one without the glycation agent (Abeta42NG).  
Figure 4.4 Fluorescence excitation spectra of 10 mM MGO dissolved in phosphate buffer and 
incubated at 37 °C. 
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The data reported in Figure 4.5 indicate some differences between AGEs formed by 
Abeta42 and Abeta40 since, during the reaction time course, there is a fluorescence 
signal build up when excited at 340 nm, but the emission maximum is red shifted with 
respect to the shorter peptide, being centred at 430 nm. This effect could be due to a 
different product or to a different conformation of Abeta42 in solution that could 
modify the environment of Arg5 because, as reported later in this chapter, the 
glycation does not hamper the transition to -sheet structure. Even if the 5Arg is not 
in the fibril inner core according to the last structural model published [62], its 
chemical environment is likely to be different respect to Abeta40, which remains 
unstructured in the glycated peptide. The reaction is also slower, likely due to this 
conformational difference, and reaches plateau after about one week, as reported in 
figure 4.6. 
 
 
Figure 4.5 Fluorescence emission spectra of Abeta42G. 
 Chapter 4: Effect of glycation on structure and aggregation properties of Abeta peptides  
65 
 
 
4.2.2 Effects on secondary structure 
The effect on the secondary structure was monitored by CD spectroscopy both on 
glycated and non-glycated peptide. The AbetaNG undergoes a transition from a 
disordered conformation to a -structure after two days, followed by a drop of the CD 
signal during the experiment timeframe that indicates peptide aggregation. On the 
other hand, AbetaG shows a random coil spectrum for the whole experiment 
timeframe; the signal slightly drops after four days of incubation, but the peptide is 
not able to undergo the transition to a -structure anymore. Thus, the glycation boosts 
the solubility of Abeta40 and prevents the transition to -structure. CD spectra of 
Abeta40NG and Abeta40G are shown separately in Figure 4.7 and Figure 4.8. 
Figure 4.6 Fluorescence intensity in correspondence of the emission maximum in function of time. 
When not visible the error bar is within the symbol. 
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Figure 4.7 CD spectra of Abeta40NG. 
Figure 4.8 CD spectra of Abeta40G. 
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The CD spectra of Abeta42NG shows the usual behaviour: it is random coil when just 
dissolved in the buffer solution. After a lag phase, it forms -sheet structures, whose 
minimum is red shifted during the incubation time respect to canonical -sheet 
structure CD lineshape; this kind of behaviour is widely reported in literature and is 
related to the formation of -structured soluble oligomers [77]; then the signal drops 
due to peptide aggregation. The CD spectra are shown in figure 4.9. As expected on 
the basis of fluorescence results, the effect of the glycation reaction on Abeta42 
secondary structure is different with respect to Abeta40. In particular, also when 
modified by the reaction, the glycated peptide is able to undergo the transition to -
sheet structure, with the minimum slightly red shifted, but the spectra intensity and as 
lineshape remain stable for the whole timeframe of the experiment, as shown in figure 
4.10. These results suggest that the structural modifications caused by glycation slow 
down the peptide aggregation as ; furthermore, the difference of the minimum position 
between Abeta42G and Abeta42NG could be related to the formation of different 
sized oligomers. 
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Figure 4.9 CD spectra of Abeta42NG. 
Figure 4.10 CD spectra of Abeta42G. 
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In addition, considering that Abeta42G is still able to adopt a -sheet conformation 
(never observed for Abeta40G), and to form aggregates, its aggregation propensity 
was studied by ThT binding assay, and compared with that of Abeta42NG. There are 
two main differences between the two peptides: i) the plateau in the fluorescence 
signal is reached faster by Abeta42NG (two days) than by Abeta42G (three days); ii) 
the plateau signal of Abeta42NG is two times higher with respect to the glycated 
peptide. These data corroborates the hypothesis that glycation hampers Abeta42 
peptide aggregation, by slowing it and possibly avoiding the formation of more mature 
aggregates. 
 
4.3 Apolar environment 
The glycation reaction was performed also in the HFIP mixture. Using this less polar 
solution, Abeta peptides adopts -helical conformation and are not able to aggregate 
to amyloid fibrils, resulting in a very stable sample. The AGE fluorescence reaches 
Figure 4.11 ThT fluorescence normalised intensity (485 nm) in function of incubation time. 
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the maximum value after about one week for both peptides, but in case of Abeta40G, 
the signal slightly drops before reaching a plateau; both kinetics are shown in figure 
4.12. In this condition, the excitation wavelength of MGO intrinsic fluorescence is 
blue shifted to about 340 nm, the same wavelength of AGEs excitation. In this 
solution, the contribution of MGO to the fluorescence signal is not negligible as in 
aqueous solution. The fluorescence spectra of Abeta40G and Abeta42G do not show 
any difference. During the incubation, together with the signal increase there is also a 
marked shift of AGEs emission maximum, from about 400 nm to 430 nm, for both 
peptides, indicating that the AGEs are changing during the incubation at 37 °C. A 
possible explanation could be that the rearrangement of glycation early-products into 
end-products is slower in apolar environment. More work is needed to further 
characterize this behaviour. As representative example, the Abeta42G fluorescence 
spectra and the same spectra subtracted MGO contributions are shown in figure 4.13.  
 
 
 
 
 
Figure 4.12 Fluorescence intensity in correspondence of the emission maximum in function of time.  
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CD spectra of both peptides in this condition show a predominant -helical structure, 
as expected [16]. There is no difference between unmodified and glycated Abeta 
peptides; as representative example, Abeta42G spectra are reported in figure 4.14. 
These results indicate that glycation does not modify the secondary structure features 
in this condition. Moreover, the CD signal is constant even after one month of 
incubation at 37 °C, confirming that the peptides are not able to aggregate in this kind 
of solution. 
Figure 4.13 Fluorescence emission spectra of Abeta42G in HIFP/phosphate buffer 80/20 v/v (left 
panel); Fluorescence emission spectra of Abeta42G after subtraction of MGO contribution (right 
panel). 
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4.4 Conclusions 
In conclusion, the glycation reaction was biophysically characterized for both amyloid 
peptides Abeta40 and Abeta42, in polar (aqueous phosphate buffer) and apolar 
(HFIP/phosphate buffer mixture) environment. The reaction kinetics and the effects 
on secondary structure were characterized in all conditions. The glycation is faster for 
the shorter peptide; this could be explained by considering an easier accessibility of 
the glycation sites . In fact, the glycation reaction completely hampers the transition 
to -sheet structures for Abeta40, that remains in unstructured state for the whole 
experiment timeframe, and therefore arginine and lysine side chains are more 
available for the reaction. In case of Abeta42, glycated peptide is still able to form -
sheet structure, but CD data indicate that these species are different from the ones 
formed by the unmodified peptide and they are more soluble in water solution. ThT 
data for Abeta42G also indicate a slowed aggregation process after peptide glycation. 
Figure 4.14 CD spectra of Abeta42G in HFIP/NaP 200 mM pH 7.4. 
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Still more work is needed to characterize glycation reaction in HFIP containing 
solution, but fluorescence data clearly indicate that the reaction take place also in this 
condition, without affecting peptides secondary structure. The HFIP mixture could be 
a very good model system to identify and structurally characterize AGEs formed by 
Abeta peptides with other biophysical techniques, thanks to the decoupling of 
glycation and aggregation processes. 
4.5 Experimental Section 
4.5.1 Materials 
Recombinant Abeta40 was expressed in E.Coli as reported in chapter 2. Abeta42 was 
synthetized as previously described [16]. MGO was purchased from Sigma-Aldrich 
and further purified by steam distillation. All other laboratory reagents were 
purchased from Sigma-Aldrich (St. Louis, Missouri, USA). 
4.5.2 Samples preparation 
Before each experiment, Abeta peptides were treated with pure TFA in order to 
dissolve any pre-existent fibril aggregate [16], as reported also in section 3.7.3. The 
peptides were dissolved in phosphate buffer 200 mM pH 7.4 to the final concentration 
of 100 M, or in HFIP/phosphate buffer 200 mM pH 7.4 mixture to the final 
concentration of 50 M. Half of the aliquots were incubated at 37 °C without agitation 
(non glycated peptides, Abeta40NG and Abeta42NG), in the other half MGO was 
added in 100 fold molar excess, i.e. 10 mM in phosphate buffer experiments, and 5 
mM in HFIP mixture experiments, and then incubated at 37 °C without agitation 
(glycated peptides, Abeta40G and Abeta42G). 
4.5.3 Fluorescence spectroscopy 
Fluorescence spectra were recorded on a Jasco FP 6600 and on HORIBA Fluoromax-
4 spectrofluorimeters. For AGEs measurements, excitation wavelength was set to 340 
nm, emission range from 370 to 550 nm, scanning speed 100 nm/min, both excitation 
 Chapter 4: Effect of glycation on structure and aggregation properties of Abeta peptides  
74 
 
and emission slits were set to 5 nm. For excitation spectra measurements, emission 
wavelength was set to 430 nm, and a range from 300 to 420 nm was explored. AGEs 
fluorescence was measured directly, without dilute the samples. For ThT 
measurements, excitation wavelength was set to 440 nm, emission range from 460 to 
600 nm, scanning speed 100 nm/min, both excitation and emission slits were set to 5 
nm. Before each measurement, a sample aliquot was taken and diluted to 10 M in 
phosphate buffer 20 mM pH 6.8 containing 30 M ThT (3 fold molar excess of ThT). 
AGEs fluorescence emission intensity, after subtraction of non-glycated peptide and 
eventually MGO contributions, was internally normalized for each experiment, in 
order to be able to compare different experiments. ThT fluorescence emission 
intensity, after subtraction of sample without ThT contribution, was normalized with 
respect to the intensity of 30 M solution of the same ThT batch, recorded in the same 
day of the experiment. All spectra were recorded at 20 °C. 
4.5.4 Circular Dichroism spectroscopy 
CD spectra were recorded on a Jasco spectropolarimeter. In phosphate buffer, a range 
from 200 to 260 nm was explored; due to buffer very high concentration, was not 
possible to explore lower wavelength because detector potential was too high. In HFIP 
mixture, a range from 190 to 250 nm was explored. The scanning speed was set to 20 
nm/min, the average time to 4 seconds and the temperature to 20 °C for all 
experiments. 
 Chapter 5 – High-resolution analysis of hemopressin peptides conformation  
75 
 
Chapter 5 – High-resolution analysis of hemopressin 
peptides conformation 
 
5.1 Work Outline 
Hemopressin (Hp) is a nonapeptide of sequence PVNFKLLSH derived from 
hemoglobin -chain acting as CB1 receptor endogenous inverse agonist, and exerting 
antinociceptive, hypotensive and anoretic activity [140,141]. Its promising 
applications in obesity and pain therapy has been hampered by the lack of 
reproducibility associated to its usage in pharmacological assays, which can be related 
to its aggregation propensity. Under specific experimental conditions (1 mM peptide 
in 25 mM phosphate, 50 mM NaCl, pH 7.4), hemopressin is able to self-assembly into 
amyloid like nanostructured fibrils [18], which may contribute to its unreliable 
activity. 
N-terminally extended isoforms of hemopressin, such as RVD-hemopressin (RVD-
Hp), were identified and reported to be CB1 agonists [143]. Notably, RVD-Hp shows 
no fibrillation in the experimental conditions reported above [18], despite the high 
sequence identity with Hp.  
Very little is known about hemopressin peptides conformation, which knowledge 
could be helpful in understanding the reasons for such different biological and 
biophysical properties that characterise these two peptides. 
In this chapter, a conformational analysis of the hemopressin peptides Hp and RVD-
Hp is reported. Conformational features were explored by a two-level approach: an 
initial screening was performed by CD spectroscopy; subsequently, a more detailed 
analysis was performed by high-resolution NMR spectroscopy. Furthermore, the 
influence of two parameters, i.e. pH and solvent polarity, was explored. In particular, 
almost neutral pH 7.4 and acidic pH 3.0 were studied. It has been reported that at 
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neutral pH, only Hp is able to form amyloid fibrils, while no aggregation occurs for 
the longer peptide; moreover at acidic pH, Hp loses its capacity to self-assemble [193].  
The second parameter explored is the solvent polarity. The two peptides were titrated 
with a fluorinated alcohol, hexafluoroisopropanol (HFIP), a solvent often used to 
simulate low polarity environments, in which intrapeptide interaction are favoured 
with respect to peptide-solvent interaction, inducing more ordered conformations.  
5.2 CD spectroscopy screening 
5.2.1 Aqueous environment 
A conformational screening was performed on both peptides by CD spectroscopy. Hp 
and RVD-Hp were dissolved in 20 mM NaP buffer at both pH 3.0 and pH 7.4, in order 
to assess the pH effect on peptides conformations. The CD spectra overlay is reported 
in figure 5.1. 
 
Although CD signal is quite low, figure 5.1 shows that the shorter peptide, Hp, is 
sensible to pH condition. Indeed, when dissolved in acidic pH it shows a spectrum 
Figure 5.1 CD spectra of hemopressin peptides in aqueous environments. The used buffer was NaP 
20 mM for both pHs. 
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corresponding to an -helical conformation. The minima position are shifted with 
respect to the canonical position, (202 nm against 208 and 227 nm against 222), likely 
because the peptide explores different conformations in solution. On the other hand, 
at neutral pH the spectrum shape changes significantly, hinting at a conformational 
transition and possibly indicating that Hp assumes a -sheet-like conformation. This 
is in agreement with the amyloid fibril formation observed for Hp at this pH, even if 
in different concentration and ionic strength conditions [18]. 
The spectrum of RVD-Hp instead is less sensible to pH condition. In both pHs 
explored, the longer peptide shows a spectrum that indicates a partial -helical 
conformation. However, at neutral pH the CD intensity is higher and the spectrum 
minima are closer to the canonical values, indicating that a neutral pH stabilise the 
helical conformation for this peptide.  
5.2.2 Apolar environments 
The two peptides were titrated, at both pHs, with HFIP. The spectra obtained are 
shown in figure 5.2 and 5.3, respectively for Hp and RVD-Hp. 
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Figure 5.2 CD spectra selection of Hp dissolved in different HFIP/ NaP 20 mM mixtures at two 
different pHs. 
Figure 5.3 CD spectra selection of RVD-Hp dissolved in different HFIP/20 mM NaP mixtures at 
two different pHs. 
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The solvent polarity titration gave similar results for the two peptides. Even a low 
amount of HFIP, i.e. 10 % v/v, is enough to stabilise the helical conformation for both 
peptides, also for Hp at pH 7.4, whose spectrum changes dramatically with respect to 
the one measured without cosolvent (figure 5.1). The increase in the HFIP 
concentration is able to enhance the CD signal, further stabilising this conformation. 
The maximum signal is reached between 40 and 60 % of cosolvent in the case of Hp, 
and between 40 and 70% in the case of RVD-Hp. Adding HFIP above these values 
caused a reduction in the signal, probably due to little destabilisation of this 
conformation in low polar environment. 
A comparison of the spectra recorded in HFIP/NaP 50% v/v at both the explored pHs 
is shown in figure 5.4. Also in this mixture, Hp is more sensitive to pH change, 
showing a signal definitely higher at pH 7.4 with respect to pH 3.0; in the case of 
RVD-Hp, there is a similar effect, although with smaller changes. Moreover, the two 
peptides show a similar spectrum at neutral pH, both in terms of lineshape and 
intensity.  
 
Figure 5.4 CD spectra comparison of the two peptides dissolved in the mixture 50/50 % v/v of 
HFIP/NaP at two different pHs. 
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5.3 NMR analysis 
5.3.1 Aqueous environments 
For each condition explored, a set of two-dimensional homonuclear experiments 
(TOCSY, NOESY, ROESY and COSY), and one carbon-correlated heteronuclear 
experiment were recorded for both Hp and RVD-Hp, at pH 3.0 and pH 7.4.. The 
experiments were carried-out  at the Bijvoet Center for Biomolecular Research 
(Utrecht, The Netherland) on a 900 MHz instruments equipped with a cryoprobe, in 
order to maximize sensitivity and resolution. More details about the experiments set-
up are reported in the experimental section. Most of proton and carbon atoms (beside 
carbons involved in CO groups) were assigned with the dataset recorded; the chemical 
shift tables for each condition are reported in Appendix A. For sake of simplicity, the 
RVD-Hp residues numbering will be used for both peptides. 
Unfortunately, very few NOE crosspeaks are present in the NOESY spectra, due to a 
bad combination of instrument magnetic field and peptides tumbling times, but also 
due to the lack of ordered structure, as expected for small-size linear peptides in 
aqueous media  [194].  
Surprisingly, during the long time necessary for NMR data acquisition, the spectra of 
both the peptides when dissolved at pH 3.0 showed clear changes with the time. The 
comparison of the amide region of 1D proton spectra of Hp at pH 3.0 recorded at 
different time and reported in figure 5.5, highlights these changes. A similar effect 
was detected also for RVD-Hp at pH 3.0, but the effect was less pronounced (figure 
5.6). On the other hand, no changes in the spectra were detected at pH 7.4. A possible 
explanation of this behaviour is that Hp undergoes a slow transition between two 
different conformations during the experiment timeframe; thus, the spectrum recorded 
just upon dissolution slowly disappears, and different signals arise from the baseline, 
corresponding to a new conformation. Moreover, in the spectrum recorded after two 
days the presence of both initial and final conformation spectra is visible. The 
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assignment of the second conformation of Hp dissolved at pH 3.0 is complicated due 
to this conversion, and is still in progress. 
 
 
 
 
Figure 5.5 Comparison of the amide region of Hp dissolved in NaP 20 mM pH 3.0 of 1D proton 
spectra recorded at different time points. 
Figure 5.6 Comparison of the amide region of RVD-Hp dissolved in NaP 20 mM pH 3.0 of 1D 
proton spectra recorded at different time points. 
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A preliminary analysis of these data was performed. In particular, the amide protons 
peak area drop over time was analysed in detail for both peptides. The trends reported 
in figure 5.7 and figure 5.8, respectively for Hp and RVD-Hp, show that the C-
terminal region peaks drop faster with respect to the N-terminal ones, suggesting that 
those residues drive the conformational transition for both peptides. Notably, the C-
terminal region was found to adopt ordered conformations when the peptide is 
dissolved in less polar environments (see section 5.3.2). 
 
 
Figure 5.7 Peak area trends over time of amide proton peaks of Hp dissolved in NaP 20 mM pH 3.0. 
Only the peaks that could be unambiguously assigned are reported in this graph. 
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5.3.2 Apolar environments 
For each condition explored, a similar NMR dataset discussed in section 5.2.2 was 
recorded (TOCSY, NOESY, ROESY, COSY and 13C-HSQC). Four different 
conditions were studied: Hp dissolved in either 50/50% v/v HFIP/NaP at pH 3.0 and 
at pH 7.4; RVD-Hp dissolved in either 50/50% v/v HFIP/NaP at pH 3.0 and at pH 7.4. 
All protons and carbon atoms (beside carbons involved in CO groups) were assigned 
with the dataset recorded; the chemical shift tables are reported in Appendix A. 
Moreover, a peptide structure model was computed for each condition using the NOE 
restrains obtained. The models were obtained using the ARIA software package, 
minimised in vacuum; the parameterization of the 50/50% HFIP/Water mixture is 
Figure 5.8 Peak area trends over time of amide proton peaks of RVD-Hp dissolved in NaP 20 mM 
pH 3.0. Only the peaks that could be unambiguously assigned are reported in this graph. 
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under development. For each condition, the lowest energy structure is reported. The 
results will be presented separately for each pH condition.  
The Hp spectra dissolved at pH 3.0 show a good signal dispersion for NH and -
protons. The bar diagram shows some medium range NOE contacts hinting at a 
structured region involving the C-terminal residues of the peptide (figure 5.9). The 
qualitative analysis of the bar diagram, in particular, the low intensity of the N i,i+1 
contacts, the high intensity of the NN i,i+1 and the presence of i,i+3 contacts, points 
toward the presence of short stretch of a helical/type I -turn conformation 
encompassing the residues from 7Phe to 12His. 
 
 
Figure 5.9 Bar diagram of Hp 500 M dissolved in HFIP/NaP 20 mM pH 3.0 50/50% v/v; the bar 
width represent the crosspeak intensity. 
 Chapter 5 – High-resolution analysis of hemopressin peptides conformation  
85 
 
In order to identify a possible structure giving a major contribution to the NOE pattern, 
the distance restrains were used to generate peptide structure. Even though the final 
structures bundle is highly variable, as expected on the basis of the short peptide 
length, the computed structures corroborate the bar diagram analysis, showing a 
structured -helical region that resembles an encompassing residues 8Lys to 11Ser; a 
representative model is shown in figure 5.10. 
 
 
In the case of RVD-Hp, at pH 3.0 the 6Asn -proton is not visible in the TOCSY and 
NOESY spectra, because it is hidden under the water signal. Moreover, the leucines 
HN and alpha protons are very close, and for this reason, some sequential NOE 
contacts cannot be unambiguously assigned (figure 5.11).  These missing contacts due 
to signal overlapping are shown with an empty box. However, more medium-range 
contacts are present in this condition and the structured region appears to be longer, 
encompassing residues from 5Val to 12His; also two -helix diagnostic i,i+4 were 
detected, encompassing respectively 7Phe to 11Ser and 8Lys to 12His. This data 
Figure 5.10 Representative structure model of Hp 500 M dissolved in HFIP/NaP 20 mM pH 3.0 
50/50% v/v. 
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suggest that the N-terminal extension makes the helix conformation more stable, and 
slightly longer. 
 
The presence of a longer structured region in the peptide core sequence residues is 
highlighted also by the computed structures, showing an ordered region encompassing 
residues from 6Asn to 11Ser, as shown by a representative model in figure 5.12. 
 
Figure 5.11 Bar Diagram of RVD-Hp 500 M dissolved in HFIP/NaP pH 3.0 50/50% v/v. 
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The Hp spectra show good signal dispersion also when dissolved at pH 7.4. However, 
less NOE contacts, and weaker with respect to the ones measured at pH 3.0 were 
detected. In particular, diagnostic signals involving 12His disappear, suggesting that 
the C-terminal end is less structured in this case (figure 5.11). Accordingly, the 
computed structures suggest the presence of a type I -turn in this pH condition, 
involving residues from 7Phe to 10Leu, as shown in figure 5.12.  
Figure 5.12 Representative structure model of RVD-Hp 500 M dissolved in HFIP/NaP 20 mM pH 
3.0 50/50% v/v. 
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Figure 5.11 Bar diagram of Hp 500 M dissolved in HFIP/NaP 20 mM pH 7.4 50/50% v/v. 
Figure 5.12 Representative structure model of Hp 500 M dissolved in HFIP/NaP 20 mM pH 7.4 
50/50% v/v. 
 Chapter 5 – High-resolution analysis of hemopressin peptides conformation  
89 
 
 
In the case of RVD-Hp, at pH 7.4 the HN protons of 6Asn and 7Phe are coincident, 
as well as and the -protons of 10Leu and 11Ser. As for the shorter peptide, less 
medium-range NOE contacts are detected when the peptide is dissolved at neutral pH, 
indicating a less ordered structure, and the bar diagram appearance points toward the 
-turn classification, even though one i,i+3 and one i,i+4  contacts, are still present, 
as shown in figure 5.13. 
 
Also in this case the computed structures highlights a shorter structured region at this 
pH, encompassing residues from 7Phe to 10Leu, as shown by a representative model 
in figure 5.14. 
Figure 5.13 Bar diagram of RVD-Hp 500 M dissolved in HFIP/NaP 20 mM pH 7.4 50/50% v/v. 
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The chemical shift index analysis was performed on the obtained backbone chemical 
shifts. Unfortunately, there are not reference chemical shift values for random coil 
conformation in HFIP solution, due to a lack of statistical information in such 
solutions. Therefore, the results obtained from this analysis are not completely 
reliable. Still, a comparison of the chemical shift between the two peptides, referred 
to the same experimental conditions can be used to highlight the main differences 
explored at local level. To this purpose, the -proton chemical shifts obtained for the 
two peptides in the same condition were compared, in order to highlights the 
differences caused by the N-terminal extension. The secondary shifts of RVD-Hp with 
respect to Hp are shown in figure 5.15. In both pH conditions, the RVD-Hp shifts are 
all upfield with respect to Hp, indicating that the longer peptide has a more 
pronounced tendency to the helical conformation, in agreement with the other results 
presented in this chapter. Moreover, this kind of analysis shows that at pH 3.0 the 
peptides conformation are similar, as indicated by the lower values of the difference 
between the respective secondary shifts; at neutral pH the differences obtained are 
higher, indicating a more structured conformation for RVD-Hp, even though the high 
Figure 5.14 Representative structure model of RVD-Hp 500 M dissolved in HFIP/NaP 20 mM pH 
7.4 50/50% v/v. 
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dynamicity of these peptides hampered the confident identification of these 
conformational differences at atomic resolution.  
 
 
5.4 Conclusions 
In conclusion, a conformational screening of the two hemopressin peptides Hp and 
RVD-Hp was performed in this thesis, studying the effect of pH and solvent polarity 
on peptides structure. In aqueous environments, the peptides were found to be 
unstructured, as expected on the base of their short length, although the recorded CD 
spectra suggest that the two peptides are able to explore more ordered conformations 
in this kind of solutions. Interestingly, NMR analysis highlighted that both Hp and 
RVD-Hp undergo a very slow conformational transition at acidic pH 3.0.  More 
experiments will be performed in this condition to fully characterise this behaviour. 
Figure 5.15 -proton chemical shifts comparison between RVD-Hp and Hp at the pH conditions 
studied. 
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In less polar environments, obtained by different HFIP/NaP buffer mixtures, 
hemopressin peptides adopt a helical conformation, clearly evidenced by both CD and 
NMR spectroscopy. The qualitative analysis of the NOE patterns and the structures 
computed using the obtained distance restrains shown that acidic pH promotes this 
helical conformation. Moreover, the N-terminal extension present in RVD-Hp was 
found to stabilise this conformation with respect to Hp at both pHs considered; this 
could be a possible explanation of the different aggregation properties and biological 
activity of the two peptides. 
5.5 Experimental section 
5.5.1 Materials 
The hemopressin peptides Hp and RVD-Hp were synthetised by solid phase peptide 
synthesis by Professor Remo Guerrini of Univerisity of Ferrara. HFIP, both 
protonated and deuterated, and other laboratory reagents were purchased from Sigma-
Aldrich (St. Louis, Missouri, USA). 
5.5.2 CD spectroscopy 
Stock solution of Hp and RVD-Hp were prepared at 2 mM concentration in HCl 10 
mM. The two peptides were diluted in NaP 20 mM buffer solution at pH 3.0 and 7.4 
to the final concentration of 20 M. The same peptides concentration was used for the 
HFIP titration as well. CD were taken using Jasco J-810 spectropolarimeter (Jasco 
international Co. Ltd, Tokyo, Japan) in the range of 190–260 nm using a 0.1 cm path 
length quartz cuvette at 20 °C in continuous scanning mode (20 nm/min, with a 4.0 s 
response and a 1.0 nm band width). Spectra corresponding only to the solvent was 
subtracted from the corresponding spectrum. The data were accumulated over 3 runs, 
the presented data being the average. The results are expressed in term of molar 
ellipticity [], in unit of deg cm2/mol. 
 
 Chapter 5 – High-resolution analysis of hemopressin peptides conformation  
93 
 
5.5.3 NMR spectroscopy 
The two peptides were diluted in NaP 20 mM buffer solution, and in HFIP/NaP 50% 
v/v, at both pH 3.0 and 7.4 to the final concentration of 500 M. The NMR spectra 
were recorded on a Bruker 900 MHz instrument with cryoprobe in collaboration with 
Dr. Wienk at the Bijvoet Center for Biomolecular Research of the University of 
Utrecht, wherein a proposal submitted and accepted by the iNEXT platform. For each 
condition, a dataset comprising several two-dimensional homonuclear correlation 
spectra and one proton-carbon heteronuclear correlation spectrum were recorded. In 
details, one TOCSY spectrum (80 ms mixing time), two NOESY spectra (200 and 300 
ms mixing time), one ROESY spectrum (100 ms spinlock time) and a 13C-HSQC 
spectrum were recorded for each sample. The temperature was 298 K for all recorded 
spectra. The chemical shifts were referenced with respect to the water signal. The 
spectra were processed using TopSpin software package (Bruker, Billerica, 
Massachusetts, USA) and NMRPipe software package [195]. The data assignment 
and analysis were performed using the CCPN software package [196]. The peptides 
structure models were obtained using the ARIA software package [197]. 
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Chapter 6 – Aggregation propensity study of the sweet 
protein Y65R-MNEI 
6.1 Work outline 
In this chapter, the aggregation propensity of Y65R-MNEI was investigated by 
screening different conditions of temperature, pH and ionic strength. It is known that 
for the parent proteins, monellin and MNEI [19,160], a first partial denaturation step 
is needed to trigger the fibrillar aggregation event. Starting from this hypothesis, the 
stability of Y65R-MNEI in function of temperature was studied by Circular 
Dichroism spectroscopy. Two different pH were explored: an acidic one (pH 2.5) and 
a nearly neutral one (pH 6.8). Considering that previous studies have shown that the 
ion strength is critical for fibril formation [19], two different conditions of ionic 
strength, 0 and 150 mM of NaCl were explored.  
Using the thermal stability data as starting point, different aggregation conditions 
were evaluated by ThT assay for both pH studied, and the aggregation kinetics were 
compared. The end-point of the aggregation process was investigated by Atomic 
Force Microscopy (AFM), in order to study the different aggregate morphologies 
obtained in each condition. 
6.2 Thermal stability 
The far-UV CD spectra of Y65R-MNEI, recorded in 20 mM sodium phosphate buffer 
at pH 2.5 and 6.8, in the presence and in the absence of 150 mM NaCl, are reported 
in Figure 6.1. In agreement with previous data [198], the CD spectra indicate that the 
protein is well folded and it presents the typical features of a protein with a high 
content of β-sheets and a low content of α-helices, as expected on the high similarity 
with the structure of MNEI determined by NMR [199], and X-ray crystallography 
[200]. The presence of NaCl does not affect the secondary structure content of the 
protein. Interestingly, the CD signal is lower at acidic pH.  
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The thermal stability of Y65R-MNEI was investigated by measuring the CD thermal 
denaturation profiles in the different pH and ionic strength conditions explored, 
reported in Figure 6.2. Data obtained indicate that the protein is more stable at neutral 
pH, showing a higher melting temperature (Tm); moreover, NaCl influences the Tm 
of Y65R-MNEI only at pH 2.5. Indeed, at acidic pH, the presence of the salt leads to 
a protein stabilization of about 4°C, while no effect is observed at neutral pH. The 
measured Tm were: 66 ± 1 and 69 ± 1 °C at acidic pH respectively in absence and in 
presence of NaCl; 71 ± 1 °C at neutral pH, with no influence of ionic strength. 
Figure 6.1 Comparison of CD spectra of Y65R-MNEI in 20 mM NaP at two different pHs and ionic 
strengths. Protein concentration was 0.2 mg/ml and the temperature 20 °C for all spectra. 
 Chapter 6 – Aggregation propensity study of the sweet protein Y65R-MNEI  
96 
 
 
6.3 Thioflavin T assays 
Thermal denaturation data provide a rational basis to select incubation temperatures 
suitable to prompt protein aggregation, since partial protein unfolding represents a 
preliminary step in the formation of amyloid-like protein fibrils [201]. Based on the 
results of the CD thermal denaturation profiles, two different temperatures were 
selected: 70°C, which corresponds to the Tm of Y65R-MNEI at pH 2.5 with 150 mM 
NaCl and at pH 6.8; 75 °C, which is a temperature higher than Tm in all conditions 
explored. Moreover, the latter temperature corresponds to the almost complete 
denaturation of the protein at pH 2.5 without any salt, i.e. to the state of the parent 
protein MNEI in the reference experiments [160]. A preliminary investigation of the 
aggregation process was performed by ThT fluorescence assay at the two selected 
temperatures, using a protein  sample dissolved at 3 mg/ml in 20 mM sodium 
phosphate at pH 2.5 and pH 6.8, with and without 150 mM NaCl. The time course of 
the aggregation reaction has been followed for one week, i.e. until a clear ThT 
Figure 6.2 Thermal denaturation profiles of Y65R-MNEI in 20 mM NaP at two different pHs and 
ionic strengths, as followed by CD spectroscopy signal at 215 nm; the heating rate was 1 °C/min, 
protein concentration 0.2 mg/ml. 
 Chapter 6 – Aggregation propensity study of the sweet protein Y65R-MNEI  
97 
 
fluorescence intensity plateau was detected. ThT fluorescence intensities in function 
of time are reported in figure 6.3. Some differences in the kinetics of ThT binding are 
revealed by these experiments:  
• The pH strongly influence ThT behaviour. At neutral pH, the fluorescence 
reaches a plateau very quickly, i.e. within 24 hours of incubation, and the measured 
intensity is definitely lower with respect to acidic pH, for both studied temperature. 
Moreover, these samples show visible aggregates since the first day of incubation. 
• At both temperatures studied, only at pH 2.5 without NaCl the curves show a 
kind of sigmoidal lineshape, formed by a lag, elongation and plateau phase, as 
expected for amyloid fibrils formation by a nucleation dependent mechanism [202]. 
Moreover, raising the temperature from 70 to 75 °C decrease the length of the lag 
phase (from about one day to about 6 hours), speeding up the aggregation process. 
• The ion strength has no effect on the neutral pH kinetic, as for the thermal 
stability. On the other hand, it has a huge effect at acidic pH. At both temperature 
studied, no lag phase is detected when NaCl is present in the samples. Moreover, this 
condition shows the highest fluorescence intensity end-point at both temperature. 
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6.4 Atomic Force Microscopy 
In order to reveal the nature of the aggregates that are formed at 70 and 75°C, the 
protein samples after 1 week of incubation for each condition studied (different 
temperatures, pHs and ionic strength) have been analysed by atomic force microscopy 
(AFM). Protein samples were also investigated before starting the incubation at high 
temperature, and no aggregates were detected (data not shown). Coexistence of fibril 
morphology and amorphous aggregates was detected in only two conditions: at pH 
2.5, without NaCl, both at 70 and 75 °C. On the other hand, only amorphous 
aggregates were detected in all the other conditions explored.  
The fibrils width and height were analysed in details; AFM images of Y65R-MNEI 
fibrils and the height profiles obtained are reported in figure 6.5. The fibrils obtained 
in the two conditions show a similar width around 50 nm, but different heights: fibrils 
formed at lower temperature (70 °C) are higher with respect to the ones formed at 75 
°C. The height ranges are respectively between 4-8 nm for the former and of about 3 
nm for the latter. Considering the amyloid fibril models already published, the 
aggregates dimensions observed are in good agreement with fibrils formed by other 
Figure 6.3 ThT binding assay of Y65R-MNEI. Fluorescence values were recorded at 485 nm at the 
time indicated upon incubation of the protein at 70 °C (left panel) and 75 °C (right panel) for one 
week. 
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proteins. The detected fibril morphologies could be related respectively to protofibril 
and protofilament stages, even if fibrils dimension can differ widely investigating 
different proteins [203]. 
 
AFM data actually show amorphous aggregates also at acidic pH in presence of NaCl, 
at both temperature; the ThT assay performed on these samples showed the highest 
fluorescence intensity. A possible explanation for these false positives could be found 
considering that also the Y65R-MNEI native structure is rich in -sheet [200], thus is 
possible that these kind of aggregates are characterized by a -sheet based quartenary 
structure, to which ThT binds. On the other hand, the kinetic of ThT binding, shown 
in figure 6.3, revealed to be diagnostic of fibrils formation. Indeed, only in the 
conditions that shown a sigmoidal lineshape, fibril morphologies was detected. This 
Figure 6.5 AFM images and height profiles of fibrils formed by Y65R-MNEI at acidic pH at 70 °C 
(left panel) and 75 °C (right panel). The segments from which the profiles were extracted are 
highlighted in the figures. 
1 
2 
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kind of kinetics indicates a nucleation dependent mechanism for the aggregation, 
which is by now the most accepted kinetics model for amyloid fibril formation [202]. 
6.5 Conclusions 
In conclusion, the aggregation propensity of Y65R-MNEI in different conditions of 
pH, temperature and ionic strength were investigated, identifying for the first time two 
conditions in which the sweet protein forms aggregate with fibril morphology. The 
first one is 20 mM NaP pH 2.5, no NaCl at 70 °C; the second one is 20 mM NaP pH 
2.5, no NaCl at 75 °C. These fibrils aggregates enhance ThT fluorescence, with a 
sigmoidal kinetics lineshape compatible with a nucleation dependent mechanism, and 
the aggregates dimensions compatible with that of amyloid fibrils. Even if a first 
thermal denaturation step is needed to trigger Y65R-MNEI aggregation, the 
temperature was not a critical parameter for fibrils formation. Instead, pH had a 
dramatic influence on Y65R-MNEI aggregation behaviour. At acidic pH, Y65R-
MNEI forms aggregated rich in -sheet, as detected by ThT assays, showing fibrillar 
morphology at low ionic strength (0 mM NaCl) and amorphous morphology at high 
ionic strength (150 mM NaCl). The faster aggregation kinetics (with no lag phase) in 
presence of salt could promote the formation of off-pathway aggregates, still detected 
by ThT due to the high -sheet content. At neutral pH, although the protein undergoes 
aggregation, visible also by eye, these species do not show the typical amyloid 
properties as evidenced by ThT fluorescence and AFM analysis. 
6.6 Experimental Section 
6.6.1 Materials 
Recombinant Y65R-MNEI was expressed in E.Coli as described elsewhere [159]. 
AFM accessories (sample supports, mica sheets, AFM tips) were purchased from 
Bruker (Billerica, Massachusetts, USA). ThioflavinT and other laboratory reagents 
were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). 
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6.6.2 Circular Dichroism 
Circular dichroism (CD) measurements have been performed on a Jasco J815 
spectropolarimeter (Jasco, Essex, UK), equipped with a temperature control system, 
using a 1-mm quartz cell in the far-UV range 200–250 nm (20 nm/min scan speed). 
Raw spectra have been corrected for buffer contribution. The thermal denaturation 
curves have been obtained at different pH and ionic strength conditions: 20 mM NaP 
pH 2.5; 20 mM NaP pH 2.5 with 150 mM NaCl; 20 mM NaP pH 6.8; 20 mM NaP pH 
6.8 with 150 mM NaCl. The CD signal at 215 nm (-sheet minimum) was followed 
in the thermal denaturation experiments, with a heating speed of 1 °C/min, from 35 to 
90 °C. The data were converted into protein unfolded fraction as reported in literature 
[204]. In all experiments, protein concentration was 0.2 mg/ml. 
6.6.3 ThioflavinT assay 
The protein (3 mg/ml) were incubated at 70 and 75°C in 20 mM phosphate buffer at 
pH 2.5 and 6.8 in absence and in presence of 150 mM of NaCl. At each aggregation 
kinetics time point, a sample aliquot of 15 l was withdrawn and diluted to 10 M in 
20 mM NaP pH 6.8 containing 30 M of ThT just before the spectral acquisition. 
Fluorescence emission spectra were acquired on a HORIBA Fluoromax-4 in the range 
460–600 nm with scan speed of 100 nm/min, upon excitation at 440 nm. Excitation 
and emission slits were both set at 5 nm. Fluorescence intensity values at 485 nm were 
normalized with respect to the values obtained for a 30 M ThT sample recorded in 
the same day, and plotted as a function of time. The reported values represent the 
means from three independent experiments. 
6.6.4 Atomic Force Microscopy 
The protein (3 mg/ml) was incubated at 70 and 75°C in 20 mM phosphate buffer at 
pH 2.5 and 6.8 in absence and in presence of 150 mM of NaCl. Just before and after 
one week of incubation, a sample aliquot was withdrawn and diluted 100-fold (0.03 
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mg/ml) in ultrapure water, deposited on a clean mica sheet and gently dried. The mica 
was then washed with ultrapure water to remove any deposited salt (phosphate or 
NaCl) and gently dried again. AFM measurements were carried out in collaboration 
with the research group of Prof. Claudio De Rosa and Dr. Rocco Di Girolamo of 
University of Naples “Federico II”, on a Bruker Multimode 8, in tapping mode, using 
a silicon cantilevers TESP-MT, tip with radius of about 8 nm, at resonance frequency 
and force constant of about 250 kHz and 50 N/m, respectively. Images were taken in 
air under ambient conditions at a scan frequency of 1 Hz. Scans size were varied from 
2 x 2 m to 0.5 x 0.5 m, depending on sample homogeneity. 
  
 Final Remarks  
103 
 
Final Remarks 
Amyloid fibrils are involved in a wide range of cellular processes, both functional and 
pathological. Several human diseases are related to the formation of amyloid 
aggregates, including very severe neurodegenerative diseases, such as Alzheimer 
disease. The exact processes that lead to the polymerization of such different 
polypeptides and also their relationship with the toxicity mechanisms are poorly 
understood. A better understanding of the amyloid aggregation process would be very 
helpful for the identification of the key therapeutic targets of amyloidosis. 
To provide structural and biophysical insights on the molecular mechanism of 
amyloid aggregation, in this thesis, different hallmarks that affects the polypeptide 
aggregation process were studied, using an integrated biophysical approach. Three 
different molecular models were chosen for these studies. All of them are able to form 
amyloid fibrillar aggregates, and they were studied at different levels of deepness in 
literature, with a wide range of biophysical techniques. The first model is represented 
by amyloid beta peptides, Abeta40 and Abeta42, which are related to AD. From the 
discovery of their relation with AD, the structures and the aggregation properties of 
these peptides were extensively studied in literature; however, Abeta peptides 
properties are strictly related to the surrounding environment. Therefore, the effect of 
interaction with membranes model systems and of glycation, a non-enzymatic post-
translational modification occurring in vivo, on Abeta peptides structure and 
aggregation properties were analysed in this work. 
The oligomeric state of Abeta42 interacting with lipids depends dramatically on 
bilayer composition: simple liposomes formed by POPC were found to stabilise 
soluble Abeta42 oligomers, while a bilayer mimicking neuronal membranes lipid 
composition is not able to solubilise the peptide, likely promoting the formation of 
insoluble aggregates. Interestingly, the presence of Omega3 lipids in the biomimetic 
 Final Remarks  
104 
 
bilayer promotes the formation of Abeta oligomers, which were deeply inserted in the 
liposomes. 
The glycation reaction with MGO was found to hinder the aggregation of Abeta40 
and Abeta42 peptides, even though with different degrees. Upon addition of the 
glycating agent, Abeta40 showed a faster reaction kinetics, and the modification 
induced by this reaction inhibits peptide ability to assume a -sheet conformation. On 
the other hand, Abeta42 showed a slower kinetics, and is still able to undergo the 
conformational transition to -sheet also upon modification, although the aggregation 
propensity of the glycated peptide was found lower with respect to the unmodified 
Abeta42. The reaction was studied also in HFIP/phosphate buffer mixture; this kind 
of solution stabilises soluble Abeta peptides in -helix conformation, avoiding any 
aggregation event. Abeta peptides appears to be glycated also in this condition, but 
the presence of HFIP promotes MGO side reactions that likely interfere with AGEs 
formation. More work is needed to characterise and set up the glycation reaction in 
this solution. 
The second model is represented by hemopressin peptides, two short molecules 
deriving from hemoglobin, whose sequence differs only for a RVD N-terminal 
extension in the longer peptide, showing completely different aggregation properties. 
The ability of hemopressin to form amyloid aggregates was characterized only very 
recently, and in literature only a few information are available about the biophysical 
properties of these peptides. 
The effect of different pH and solvent polarity conditions were analysed in this thesis 
on both hemopressin peptides, Hp and the N-terminal extended RVD-Hp. In aqueous 
environments, these peptides are mainly unstructured, even though the CD spectra 
suggest the presence of some ordered conformations. Surprisingly, when dissolved at 
acidic pH, both peptides undergo a slow conformational transition detectable by 
NMR, which is still under investigation. In less polar environments, mimicked by 
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HFIP/phosphate buffer mixtures, the peptides assume more ordered conformations, as 
resulted by both CD and NMR analysis. The three extra residues present in RVD-Hp 
sequence stabilise more ordered conformations, even though in all explored 
conditions the two peptides show a high conformational dynamicity. 
The third model is an engineered sweet protein, called Y65R-MNEI, derived for the 
plant protein monellin. The parent proteins monellin and MNEI were known to form 
amyloid fibrils upon thermal unfolding but no information was available on the 
amyloid aggregation of Y65R-MNEI.  
In this thesis, a preliminary study of Y65R-MNEI aggregation properties in function 
of pH, temperature and ionic strength was performed, to identify how these crucial 
factors modulate the protein aggregation. Experimental data indicate that the crucial 
parameters affecting the aggregation mechanism is pH. Indeed, pH dramatically 
change Y65R-MNEI aggregation properties, as an acidic pH promotes the formation 
of amyloid fibrils, while neutral pH promotes the formation of amorphous, off-
pathway aggregates. 
In conclusion, the choice of these molecular models to investigate amyloid 
aggregation allowed the study of this process from different points of view, using 
several biophysical techniques. This thesis can represent a little step towards the 
elucidation of this process, whose relevance is more and more evident in biological 
and biotechnological processes. 
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Appendix A – Hemopressin peptides chemical shifts tables 
A-I Hp in NaP pH 3.0 
Residue NH H H H H H z C C C C C
4-Pro  4.34 2.37, 
1.93 
3.31  1.97, 
1.91 
 62.21 32.60 49.38  26.42 
5-Val 8.48 3.96 1.85  0.80, 
0.71 
  62.61 32.73   20.44, 
20.97 
6-Asn 8.41 4.61 2.71, 
2.63 
7.52     38.76    
7-Phe 8.15 4.44 2.94, 
3.04 
7.38 7.27  7.23 58.26 39.53    
8-Lys 8.06 4.13 1.67, 
1.62 
1.57 2.89 1.26  56.44 32.90 29.04 42.04 24.73 
9-Leu 7.91 4.22 1.52 0.86, 
0.80 
 1.51  55.08 42.24 24.79, 
23.52 
 26.94 
10-Leu 8.04 4.30 1.49, 
1.57 
0.83, 
0.77 
 1.54  54.94 42.32 24.96, 
23.30 
 26.84 
11-Ser 8.07 4.32 3.75     58.19 63.87    
12-His 8.15 4.52 3.21, 
3.07 
8.49 7.19   55.89 29.46    
 
  
 Appendix A – Hemopressin peptides chemical shifts tables  
107 
 
A-II Hp in NaP pH 7.4 
Residue NH H H H H H z C C C C C
4-Pro  4.31 2.35, 
1.91 
3.28  1.89, 
1.95 
 62.19 32.64 49.37  26.49 
5-Val 8.40 3.96 1.86  0.80, 
0.71 
  62.55 32.71   20.43, 
20.98 
6-Asn   2.71, 
2.62 
     38.82    
7-Phe 8.18 4.46 2.92, 
3.03 
    58.01 39.55    
8-Lys 8.04 4.14 1.67, 
1.60 
1.56 2.88 1.24  56.29 33.0 29.05 42.05 24.70 
9-Leu 7.96 4.21 1.51 0.85, 
0.79 
 1.49  55.13 42.27 24.80, 
23.55 
 26.99 
10-Leu 8.06 4.30 1.47, 
1.56 
0.83, 
0.77 
 1.53  54.85 42.42 24.93, 
23.32 
 26.88 
11-Ser  4.32 3.73     58.05 63.91    
12-His 7.83 4.36 3.09, 
2.95 
    57.31 30.86    
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A-III RVD-Hp in NaP pH 3.0 
Residue NH H H H H H z C C C C C
1-Arg            
2-Val 8.56     

     
3-Asp 8.63  

        
4-Pro  4.32 2.17, 
1.84 
3.75  1.92  63.16 32.09 50.70  27.22 
5-Val 8.02 3.88 1.87  0.72   62.66 32.57    
6-Asn 8.24 4.60 2.71, 
2.60 
6.81, 
7.52 
   52.73 38.67    
7-Phe 8.05 4.41 2.96, 
3.04 
7.15 7.27  7.22 58.43 39.39    
8-Lys 8.01 4.12 1.67, 
1.61 
1.56 2.89 1.25  56.47 32.02 29.02 42.05 24.74 
9-Leu 7.89 4.20 1.51 0.86, 
0.79 
 1.52  55.09 42.21 24.77,
23.52 
 26.87 
10-Leu 8.02 4.29 1.48, 
1.55 
0.83, 
0.77 
 1.50  54.91 42.35 24.93, 
23.28 
 26.93 
11-Ser 8.06 4.31 3.74     58.25 63.85    
12-His 8.15 4.51 3.07, 
3.21 
7.18 8.48   55.88 29.43    
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A-IV RVD-Hp in NaP pH 7.4 
Residue NH H H H H H z C C C C C
1-Arg            
2-Val      

     

3-Asp 8.47  

        
4-Pro  4.29 2.19, 
1.85 
3.65  1.93  63.23 32.13 50.69  27.23 
5-Val 8.11 3.87 1.91  0.74, 
0.84 
  62.99 32.38   20.91,
20.96 
6-Asn 8.19 4.59 2.70, 
2.62 
6.81, 
7.56 
   52.97 38.76    
7-Phe 7.99 4.42 2.98, 
3.04 
7.14 7.23  7.26 58.31 39.25    
8-Lys 7.96 4.14 1.68, 
1.61 
1.57 2.88 1.26  56.32 32.95 29.03 42.07 24.72 
9-Leu 7.93 4.21 1.51 0.86, 
0.80 
 1.52  55.09 42.23 24.77,
23.55 
 26.89 
10-Leu 8.03 4.30 1.47, 
1.56 
0.83, 
0.77 
 1.50  54.93 42.41 24.98, 
23.28 
 26.97 
11-Ser 8.07 4.31 3.74     58.17 63.90    
12-His 7.84 4.36 3.10, 
2.97 
6.99 8.03   57.42 30.72    
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A-V Hp in HFIP/NaP 50/50 % v/v pH 3.0 
Residue NH H H H H H z C C C C C
4-Pro  4.58 2.23, 
2.27 
3.59  2.70  62.57 26.44 49.70  32.59 
5-Val 8.07 4.20 2.07   0.92, 
1.06 
 63.03 33.41   20.40, 
19.98 
6-Asn 7.80 4.89 2.88, 
3.20 
6.39, 
7.22 
   52.59 38.06    
7-Phe 7.95 4.53 3.39, 
3.21 
7.41    60.57 39.21 51.18   
8-Lys 8.16 4.29 1.67, 
2.09 
1.92 3.20 1.64, 
1.69 
 58.91 31.99 29.02 42.31 25.06 
9-Leu 7.63 4.40 1.87 1.08, 
1.14 
 1.81  57.12 42.28 22.31,
24.03 
 27.32 
10-Leu 7.70 4.45 1.94 1.08, 
1.10 
 1.87  56.57 42.50 22.72,
24.45 
 27.15 
11-Ser 7.87 4.55 4.03, 
4.16 
    58.91 64.14    
12-His 8.08 4.81 3.48, 
3.59 
7.50 
 
   55.98 28.75 51.62   
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A-VI Hp in HFIP/NaP 50/50 % v/v pH 7.4 
Residue NH H H H H H z C C C C C
4-Pro  4.47 2.16, 
2.21 
3.07, 
3.51 
 2.64  62.53 26.65 49.59  32.71 
5-Val  4.16 2.07   0.92, 
1.04 
 63.09 33.22   20.37, 
19.98 
6-Asn 7.88 4.83 3.11, 
2.84 
6.37, 
7.17 
   52.91 38.05    
7-Phe 7.87 4.54 3.19, 
3.38 
7.52 7.39   60.15 39.11 69.67 69.59  
8-Lys 8.10 4.32 2.05, 
1.79 
1.64, 
1.90 
3.17 1.64  58.33 32.06 28.93 42.31 24.90 
9-Leu 7.63 4.38 1.79 1.05, 
1.12 
 1.99  56.84 42.28 22.42,
24.20 
 27.32 
10-Leu 7.58 4.49 1.93 1.05, 
1.09 
 1.87  56.06 42.38 22.22,
24.50 
 24.50 
11-Ser 7.83 4.55 4.02, 
4.12 
    58.68 64.20    
12-His 7.94 4.64 3.49, 
3.59 
7.50 
 
7.50   57.67 29.70    
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A-VII RVD-Hp HFIP/NaP 50/50 % v/v pH 3.0 
Residue NH H H H H H z C C C C C
1-Arg      

     
2-Val 8.42     

     

3-Asp 8.49  

        
4-Pro  4.54 2.52 4.02  2.20, 
2.27 
 64.90 31.96 50.84  27.07 
5-Val 7.61 3.99 2.21   1.05, 
1.15 
 64.94 32.05   20.43,
20.31 
6-Asn 7.90 4.72 2.95, 
3.00 
6.73, 
7.23 
   54.94 38.23    
7-Phe 8.05 4.52 3.30, 
3.36 
7.37   7.26 60.86 39.05    
8-Lys 8.21 4.23 2.17 1.92 3.19 1.71  58.91 31.93 28.90 42.31 24.82 
9-Leu 7.95 4.37 1.82, 
1.99 
1.06, 
1.16 
   57.64 42.22 22.37,
24.17 
  
10-Leu 7.94 4.42 1.80, 
1.95 
1.07, 
1.09 
   56.77 42.45 22.19, 
24.38 
  
11-Ser 7.87 4.48 3.89, 
4.10 
    58.99 64.03    
12-His 8.02 4.77 3.48, 
3.58 
7.41 7.47   56.01 28.61  51.32  
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A-VIII RVD-Hp HFIP/NaP 50/50 % v/v pH 7.4 
Residue NH H H H H H z C C C C C
1-Arg   

  

     
2-Val      

     

3-Asp 8.07  

        
4-Pro  4.18 2.23 3.70  1.86, 
2.27 
 60.61 31.70 50.54  26.86 
5-Val 7.68 3.69 1.99   0.78, 
0.85 
 65.18 31.74   20.06,
20.92 
6-Asn 7.94 4.36 2.65, 
2.67 
6.41, 
7.08 
   54.80 37.99    
7-Phe 7.94 4.18 3.03, 
3.05 
7.06   7.26 64.84 38.75 50.85   
8-Lys 7.78 3.95 1.88 1.63 2.89 1.42  58.32 31.69 28.51 42.04 24.40 
9-Leu 7.72 4.06 1.49, 
1.72 
0.76  1.63  57.23 41.92 21.91  26.81 
10-Leu 7.59 4.16 1.47, 
1.63 
0.76, 
0.77 
   56.04 42.26 23.93, 
24.22 
  
11-Ser 7.51 4.17 3.57, 
3.74 
    58.65 63.74    
12-His 7.54 4.30 3.09, 
3.19 
7.41 7.10   57.44 29.21 50.88 49.59  
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Appendix B – PhD Course Activity Summary 
Candidate: Alessandro Emendato  Supervisor: Prof. Delia Picone 
1) Attended Courses: 
 Corso avanzato di spettrometria di massa, Lecturer: Prof. Piero Pucci, 
from 30th June to 4th July 2014. 
 Analisi strutturale di materiali su scala nanometrica tramite diffusione 
di raggi X a basso angolo, Lecturer: Prof. Finizia Auriemma, from 4th to 
18th September 2015. 
 Applications of neutron scattering techniques in soft matter and bio-
relevant systems. How to study their structure and dynamics, Lecturer: 
Dott. Yuri Gerelli, from 9th to 13th November 2015. 
 Studi NMR di sistemi paramagnetici e di interazioni bio-
macromolecolari allo stato solido, Lecturer Dott. Guido Pintacuda, from 
22nd to 24th February 2016. 
 Le tecniche di estrazione solido-liquido impiegate nella preparazione del 
campione per l’analisi chimica e nella produzione di estratti per usi 
industriali, Lecturer: Prof. Daniele Naviglio, from 29th February to 3rd 
March 2016. 
 Chimica fisica degli acidi nucleici, Lecturer: Prof. Luigi Petraccone, from 
11th to 14th July 2016. 
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2) Attended Seminars: 
Title Speaker Date Place 
Incontro con la Peroni: azienda 
alimentare leader nel settore birraio 
Luigi Serino 12/05/2014 Monte Sant’Angelo, 
Naples 
DNA aptamers as new type of drugs Vera A. Spiridova 22/05/2014 Monte Sant’Angelo, 
Naples 
Protein symmetrisation as a novel tool 
in structural biology 
Francesca Coscia 28/05/2014 Monte Sant’Angelo, 
Naples 
Impact factors, citations, journal 
reputation, editorial policies 
Thierry Tron, 
Danilo Porro 
26/06/2014 Monte Sant’Angelo, 
Naples 
Material design of transition metal 
oxide alloys 
Mayal Caspary 
Toroker 
08/07/2014 Monte Sant’Angelo, 
Naples 
NMR study of bioactive protein 
conformation 
Giuseppe Nicastro 20/11/2014 National Institute for 
Medical Research, 
London 
The conformation of enkephalin bound 
to its receptor: an “elusive goal” 
beyond reality 
Domenico 
Sanfelice 
03/12/2014 National Institute for 
Medical Research, 
London 
Iron sulfor cluster protein: ISCA Matija Popovic 12/02/2015 National Institute for 
Medical Research, 
London 
Mechanistic and structural aspects of 
M. tb alanine racemase inhibition by 
D-cycloserine 
Cesira De Chiara 12/03/2015 National Institute for 
Medical Research, 
London 
Structural architecture of Trim32: a 
member of the tripartite motif E3-
ligases family 
Diego Esposito 12/03/2015 National Institute for 
Medical Research, 
London 
A new cellular model to follow 
Friedreich’s ataxia development in a 
time-resolved way 
Tommaso 
Vannocci 
30/04/2015 National Institute for 
Medical Research, 
London 
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Microscopia a forza atomica – 
applicazioni biologiche 
Alex Winkel, 
Benjamin L. 
Holmes 
19/11/2015 Monte Sant’Angelo, 
Naples 
Computational Chemistry beyond 
molecules 
Alessio Petrone 07/01/2016 Monte Sant’Angelo, 
Naples 
Biopesticides which target voltage-
gates ion channels: efficacy and 
biosafety 
Angharad M.R. 
Gatehouse 
14/01/2016 Monte Sant’Angelo, 
Naples 
Functionalized and artificial enzymes: 
new bioderived catalysts 
Thierry Tron 14/01/2016 Monte Sant’Angelo, 
Naples 
Multimodal approaches for preclinical 
molecular imaging  
Luca Menichetti, 
Mario Chiariello 
02/02/2016 Monte Sant’Angelo, 
Naples 
Probing molecular and supramolecular 
chirality by chiroptical response of 
porphyrins and metalloporphyrins 
Nina Berova 13/09/2016 Monte Sant’Angelo, 
Naples 
Biomolecular interaction analytics 
using microscale thermophoresis 
Francesca Viganò 26/10/2016 Monte Sant’Angelo, 
Naples 
Modified nucleosides and 
oligonucleotides for biomedical 
applications 
Daniela 
Montesarchio 
18/01/2017 Monte Sant’Angelo, 
Naples 
 
3) Attended Integration Exams (for candidates not graduated in Chemical 
Science): 
Title Professor Date 
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4) Visiting periods in Institutions different from University of Naples 
“Federico II”: 
Host Institution Country Start Date End Date 
National Institute for Medical 
Research 
London, 
England 
15th September 
2014 
31st August 
2015 
 
5) Publications (include submitted and in preparation): 
 Alessandro Emendato, Roberta Spadaccini, Augusta De Santis, Remo 
Guerrini, Gerardino D'Errico, Delia Picone; Preferential interaction of 
the Alzheimer peptide Aβ-(1-42) with Omega-3-containing lipid 
bilayers: structure and interaction studies, (2016), FEBS Letters, 590, 
(4), 582-91, doi: 10.1002/1873-3468.12082. 
 Rosario Oliva, Alessandro Emendato, Giuseppe Vitiello, Manuela 
Grimaldi, Anna Maria D'Ursi, Pompea Del Vecchio, Luigi Petraccone, 
Gerardino D'Errico; On the microscopic and mesoscopic perturbations 
of lipid bilayers upon interaction with the MPER domain of the HIV 
glycoprotein gp41, (2016), BBA-Biomembranes, 1858 (8), 1904-
1913, doi:10.1016/j.bbamem.2016.05.007. 
 Andrea Pica, Federica Donnarumma, Alessandro Emendato, Serena 
Leone, Michele Fortunato Rega, Rocco Di Girolamo, Antonello 
Merlino, Delia Picone; Structure and aggregation propensity of the 
super-sweet protein Y65R-MNEI, Manuscript in preparation. 
 Alessandro Emendato, Giulia Milordini, Miquel Adrover, Annalisa 
Pastore, Delia Picone; The effect of glycation on the aggregation 
properties of the Abeta peptides, Manuscript in preparation. 
 
 
 Appendix B – PhD Course Activity Summary  
118 
 
 
6) Attended congresses/workshops/summer schools/contribution: 
 May 25-26, 2014: Biophysics of Amyloids and Prions, Naples, Italy. 
Poster communication: Interaction between amyloid peptide A (1-42) 
with model phospholipid bilayers, poster award winner. 
 October, 27-29, 2015: Sigma-Aldrich Young Chemist Symposium, 
Rimini, Italy. Poster communication: Omega3 lipid amount in 
liposomes modulates their interaction with A (1-42) peptide. 
 June, 23-25, 2016: 15th Naples Workshop on Bioactive Peptides, 
Naples, Italy. 
Poster communication: High resolution NMR study of 
endocannabinoid peptides. 
 November, 7-11, 2016: Helmholtz Training Course on Integrative 
Structural Biology, Braunschweig, Germany. 
 February, 11-15, 2017: Biophysical Society 61th Annual Meeting, New 
Orleans, USA. 
Poster communication: Sweeter and stronger: structure-driven 
molecular design to enhance sweetness and stability of the single chain 
monellin MNEI. 
7) Other Activities: 
 Didactic support for the course “NMR di biomolecule”, held by Prof. 
Delia Picone, year 2015/2016. 
 PhD student representative in High School Students Orientation 
Commission, year 2016. 
 Participation at orientation event Porte Aperte: Scienze si presenta, 
22nd - 23rd Febraury 2016. 
 Participation at orientation/divulgation event Futuro Remoto, 7th – 10th 
October 2016. 
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 Didactic support for the course “NMR di biomolecule”, held by Prof. 
Delia Picone, year 2016/2017. 
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